<SEC-DOCUMENT>0001564590-18-006921.txt : 20180328
<SEC-HEADER>0001564590-18-006921.hdr.sgml : 20180328
<ACCEPTANCE-DATETIME>20180328085029
ACCESSION NUMBER:		0001564590-18-006921
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20180323
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180328
DATE AS OF CHANGE:		20180328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Xenon Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001582313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980661854
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36687
		FILM NUMBER:		18717106

	BUSINESS ADDRESS:	
		STREET 1:		200 - 3650 GILMORE WAY
		CITY:			BURNABY
		STATE:			A1
		ZIP:			V5G 48W
		BUSINESS PHONE:		(604) 484-3300

	MAIL ADDRESS:	
		STREET 1:		200 - 3650 GILMORE WAY
		CITY:			BURNABY
		STATE:			A1
		ZIP:			V5G 48W
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>xene-8k_20180323.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
xene-8k_20180323.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:1pt;line-height:1pt;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:13pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): March 23, 2018 </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">XENON PHARMACEUTICALS INC. </p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as Specified in Its Charter) </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:11.25pt;">
<td valign="bottom"  style="width:33.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Canada</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">001-36687</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">98-0661854</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:33.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr style="height:12pt;">
<td valign="bottom"  style="width:33.32%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:33.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">200-3650 Gilmore Way</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Burnaby, British Columbia, Canada</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-top:0pt;line-height:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V5G 4W8</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:33.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-top:0pt;line-height:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: (604) 484-3300</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable </p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report) </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td></tr></table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<font style="font-size:9pt;font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9746;</font></font></p>
<p style="margin-bottom:12pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="font-size:9pt;font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9746;</font></font></p>
<p style="text-align:center;margin-top:4pt;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:1pt;line-height:1pt;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt; clear:both;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:15.22%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 1.01</p></td>
<td valign="top"  style="width:84.78%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Entry into a Material Definitive Agreement.</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 23, 2018, Xenon Pharmaceuticals Inc. (the &#8220;Company&#8221;) and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund O.S., L.P., Investment 10, L.L.C. and MSI BVF SPV, L.L.C. (collectively, &#8220;BVF&#8221;) entered into an Exchange Agreement pursuant to which BVF agreed to exchange an aggregate of 2,868,000 Common Shares of the Company for 2,868,000 Series 1 Preferred Shares of the Company (the &#8220;Exchange&#8221;). The Exchange closed on March 27, 2018 (the &#8220;Closing&#8221;). BVF, along with its affiliated funds, is an existing shareholder of the Company and held a number of Common Shares of the Company representing approximately 19.9% of the Company&#8217;s outstanding Common Shares prior to the Closing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A copy of the Exchange Agreement is attached hereto as Exhibit 10.1 and is incorporated herein by reference. The foregoing is only a brief description of the material terms of the Exchange Agreement, does not purport to be complete and is qualified in its entirety by reference to the full text of the Exchange Agreement.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:15.22%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 1.02</p></td>
<td valign="top"  style="width:84.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Termination of a Material Definitive Agreement.</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="T17"></a><a name="T26"></a><a name="P290766148"></a>On March 27, 2018, the Company closed the previously announced transaction with Teva Pharmaceuticals International GmbH, along with Teva Canada Limited (collectively, &#8220;Teva&#8221;), to terminate by mutual agreement the collaborative development and license agreement dated December 7, 2012, as amended. In connection with the closing of such transaction, the Company cancelled 1,000,000 Common Shares of the Company that were owned by Teva. Pursuant to the terms of the termination agreement, Teva will also return, license or assign to the Company certain intellectual property including certain patent rights and will transfer regulatory filings related to TV-45070 to the Company. The termination agreement requires the Company to pay a low single-digit percentage royalty to Teva based on net sales of approved products, if any, resulting from any continued development and commercialization of TV-45070 by the Company during the period that assigned or licensed patents cover such products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 23, 2018, the Ontario Securities Commission issued an order granting the Company exemptive relief from the requirements related to issuer bids under applicable Canadian securities laws in connection with the transfer and assignment to the Company by Teva of the 1,000,000 Common shares that were cancelled by the Company. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For additional information regarding the termination agreement with Teva, please refer to the Company&#8217;s Current Report on Form 8-K reporting information under Items 1.01, 1.02 and 9.01, filed with the Securities and Exchange Commission on March 7, 2018, which disclosure is incorporated herein by reference.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:15.22%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 3.02</p></td>
<td valign="top"  style="width:84.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unregistered<font style="color:#000000;"> Sales of Equity Securities.</font></p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The disclosure required by this Item and included in Items 1.01 and 3.03 of this Current Report on Form 8-K (this &#8220;Current Report&#8221;) is incorporated herein by reference.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:15.22%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 3.03</font></p></td>
<td valign="top"  style="width:84.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Material Modification to Rights of Security Holders.</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Closing, the Company issued an aggregate of 2,868,000 Series 1 Preferred Shares to BVF pursuant to the terms of the Exchange Agreement and the 2,868,000 Common Shares transferred to the Company by BVF in the Exchange were cancelled. The Series 1 Preferred Shares were issued without registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 23, 2018, the Company filed articles of amendment (the &#8220;Articles of Amendment&#8221;) with the Director of Industry Canada creating an unlimited number of Series 1 Preferred Shares. The following summary of certain terms and provisions of the Series 1 Preferred Shares is subject to, and qualified in its entirety by reference to, the rights, privileges, restrictions and conditions attached to the Series 1 Preferred Shares that are set out in Schedule 1 to the Articles of Amendment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Rank<font style="font-style:normal;">. In the event of the Company&#8217;s liquidation, dissolution or winding up or other distribution of assets of the Company among its shareholders for the purpose of winding up the Company&#8217;s affairs, the holders of Series 1 Preferred Shares are entitled to all remaining property and assets of the Company </font>pari passu<font style="font-style:normal;"> on a share for share basis with the holders of the Company&#8217;s Common Shares. The holders of the Series 1 Preferred Shares are entitled to receive such property and assets of the Company prior to the receipt thereof by the holders of the Common Shares.&nbsp;&nbsp;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Conversion<font style="font-style:normal;">. Each Series 1 Preferred Share is convertible into one Common Share at any time at the holder&#8217;s option without payment of any additional consideration, provided that any such conversion must be for at least the lesser of (i) 100,000 Series 1 Preferred Shares, (ii) the remaining number of Series 1 Preferred Shares then held by such holder and (iii) such other number of Series 1 Preferred Shares as agreed between the Company and such holder. Holders of the Series 1 Preferred Shares are prohibited from converting Series 1 Preferred Shares into Common Shares if, as a result of such conversion, the holder, together with its affiliates, would beneficially own (calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and National Instrument 62-104 </font>Take-Over Bids and Issuer Bids<font style="font-style:normal;"> in Canada) more than 9.99% of the total number of Common Shares issued and outstanding immediately after giving effect to such conversion (the &#8220;Beneficial Ownership Limitation&#8221;), provided that the holder may reset the Beneficial Ownership Limitation to a higher or lower number (not to exceed 19.99% of the total number of Common Shares issued and outstanding immediately after giving effect to a conversion) upon providing written notice to the Company. Any such notice providing for an increase to the Beneficial Ownership Limitation will be effective 61 days after delivery to the Company.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Series 1 Preferred Share is also convertible into one Common Share at any time at the Company&#8217;s option without payment of additional consideration, provided that prior to any such conversion, the holder, together with its affiliates, beneficially owns less than 5.00% of the total number of Common Shares issued and outstanding and such conversion will not result in the holder, together with its affiliates, beneficially holding more than 5.00% of the total number of Common Shares issued and outstanding immediately after giving effect to such conversion.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If, at any time while the Series 1 Preferred Shares are outstanding, there occurs a Change of Control (as defined in the Articles of Amendment), holders of Series 1 Preferred Shares shall be issued one Common Share for each outstanding Series 1 Preferred Share immediately prior to the Change of Control (without regard to the Beneficial Ownership Limitation), and following such conversion, will be entitled to receive the same kind and amount of securities, cash or property that a holder of Common Shares is entitled to receive in connection with such Change of Control. </p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Voting Rights</font><font style="font-style:normal;">. The holders of the Series 1 Preferred Shares will not be entitled to receive notice of or to attend any meeting of the shareholders of the Company and will not be entitled to vot</font><font style="font-style:normal;">e at any such meeting. Notwithstanding the foregoing, the Series 1 Preferred Shares are entitled to receive notice of and attend any meeting of the shareholders of the Company and vote on all matters on which the Common Shares are entitled to vote, voting </font><font style="font-style:normal;">together with the Common Shares on an as-converted basis and as a single class, subject in the case of each holder of the Series 1 Preferred Shares to the Beneficial Ownership Limitation notwithstanding any voting or other rights the holder may have at law</font><font style="font-style:normal;"> or otherwise. In no case shall a Series 1 Preferred Share be entitled to more than one vote on an as-converted basis. Any Series 1 Preferred Shares that are ineligible to convert into Common Shares due to the Beneficial Ownership Limitation, measured as o</font><font style="font-style:normal;">f a given record date that applies for a shareholder meeting, shall be deemed to be non-voting securities. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may not, without the affirmative vote of the holders of a majority of the then outstanding Series 1 Preferred Shares, (i) alter or change adversely the powers, preferences or rights given to the Series 1 Preferred Shares or alter or amend or repeal any provision of, or add any provision to, the articles or bylaws of the Company, or file any articles of amendment, if such action would adversely alter or change the rights, privileges, restrictions and conditions provided for the benefit of the Series 1 Preferred Shares, or (ii) enter into any agreement with respect to any of the foregoing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Transferability<font style="font-style:normal;">. Prior to any sale, transfer or other disposition of Series 1 Preferred Shares, the holder must provide the Company with prior written notice at least three trading days in advance. No transfers may be effected unless the number of Series 1 Preferred Shares being transferred is at least the lesser of (i) 100,000 Series 1 Preferred Shares, (ii) the remaining number of Series 1 Preferred Shares then held by such holder and (iii) such other number of Series 1 Preferred Shares as agreed between the Company and such holder. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dividends<font style="font-style:normal;">. Holders of the Series 1 Preferred Shares are entitled to receive dividends (other than dividends in the form of Common Shares) on the Series 1 Preferred Shares (without regard to the Beneficial Ownership Limitation) if, as and when declared by the Company&#8217;s board of directors on the Common Shares.&nbsp;&nbsp;All dividends which the board of directors of the Company may determine to declare and pay must be declared and paid in equal or equivalent amounts per share on all of the Series 1 Preferred Shares in priority to the holders of the Common Shares.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Adjustments<font style="font-style:normal;">. If the Common Shares are subdivided, consolidated, reclassified or otherwise changed, the Series 1 Preferred Shares will be subdivided, consolidated, reclassified or otherwise changed in the same proportion and in the same manner. If the Common Shares are exchanged or changed into other securities, cash or other property, the Series 1 Preferred Shares when converted will be converted into such other securities, cash or other property in the same manner. If the Common Shares are converted into or exchanged for the right to receive more than one type of consideration, the consideration for which the Series 1 Preferred Shares are exchangeable will be deemed to be the weighted average of the types and amounts of consideration received by the holders of Common Shares.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Redemption<font style="font-style:normal;">. The Company may not redeem the Series 1 Preferred Shares.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A copy of the Articles of Amendment is attached hereto as Exhibit 3.1 and is incorporated herein by reference. The foregoing is only a brief description of the material terms of the Articles of Amendment, does not purport to be complete and is qualified in its entirety by reference to the full text of the Articles of Amendment. The specimen Series 1 Preferred Share certificate is attached hereto as Exhibit 4.1 and is incorporated herein by reference.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:15.22%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 5.03</font></p></td>
<td valign="top"  style="width:84.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The disclosure required by this Item and included in Item 3.03 of this Current Report is incorporated herein by reference.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:15.22%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 8.01</p></td>
<td valign="top"  style="width:84.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Events.</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the closing of the share cancellation with Teva and the Closing with BVF, as of March 27, 2018, there were 14,171,301<font style="color:#000000;font-family:Calibri;"> </font>Common Shares and 2,868,000 Series 1 Preferred Shares of the Company outstanding. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 28, 2018, the Company issued a press release announcing the closing of the share cancellation with Teva and the Closing with BVF. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:15.22%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01</p></td>
<td valign="top"  style="width:84.78%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financial<font style="color:#000000;"> Statements and Exhibits.</font></p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:472.5pt;;">
<tr>
<td style="width:90pt;"></td>
<td style="width:4.5pt;"></td>
<td style="width:378pt;"></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;Number</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="xene-ex31_8.htm"><font style="text-decoration:underline;">Articles of Amendment to the Articles of the Company, creating the Series 1 Preferred Shares.</font></a></p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="xene-ex41_7.htm"><font style="text-decoration:underline;">Specimen Series 1 Preferred Share Certificate.</font></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="xene-ex101_6.htm"><font style="text-decoration:underline;">Exchange Agreement, dated March 23, 2018, by and among the Company and the shareholders listed in Schedule B thereto.</font></a></p></td>
</tr>
<tr style="height:7.65pt;">
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr style="height:18.9pt;">
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="xene-ex991_9.htm"><font style="text-decoration:underline;">Press Release issued by Xenon Pharmaceuticals Inc. dated March 28, 2018</font></a></p></td>
</tr>
</table></div>
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0.96%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="color:#000000;font-size:6pt;">&#160;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Xenon Pharmaceuticals Inc.</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:&nbsp;&nbsp;March 28, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;<font style="font-style:italic;">Ian Mortimer</font></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ian Mortimer</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">President &amp; Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>xene-ex31_8.htm
<DESCRIPTION>EX-3.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
xene-ex31_8.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 3.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.93%;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018032803585162931798.jpg" title="" alt="" style="width:452px;height:41px;"></p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;color:#000000;font-family:Arial Bold Italic;">Canada Business Corporations Act </font><font style="color:#000000;font-family:Arial Bold;">(CBCA) <br />FORM 4</font></p>
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial Bold;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLES OF AMENDMENT <br />(Section 27 or 177)</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:15.3pt;">
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:3pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 &#8211; Current corporate name </p></td>
</tr>
<tr style="height:36.05pt;">
<td valign="middle"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:3pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="fedform_41"></a>Xenon Pharmaceuticals Inc.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:15.3pt;">
<td colspan="10" valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:3pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 - Corporation number </p></td>
</tr>
<tr style="height:5.65pt;">
<td colspan="10" valign="middle"  style="width:100%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:3pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:3.4%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:3pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="fedform_72"></a><a name="fedform_42"></a><a name="fedform_43"></a>3</p></td>
<td valign="middle"  style="width:2.56%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:3pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="fedform_73"></a><a name="fedform_44"></a>7</p></td>
<td valign="middle"  style="width:2.56%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:3pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="fedform_74"></a><a name="fedform_45"></a>5</p></td>
<td valign="middle"  style="width:2.56%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:3pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="fedform_75"></a><a name="fedform_46"></a>8</p></td>
<td valign="middle"  style="width:2.56%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:3pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="fedform_76"></a><a name="fedform_47"></a>6</p></td>
<td valign="middle"  style="width:2.56%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:3pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="fedform_77"></a><a name="fedform_48"></a>5</p></td>
<td valign="middle"  style="width:2.56%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:3pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="fedform_78"></a><a name="fedform_49"></a>-</p></td>
<td valign="middle"  style="width:2.56%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:3pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="fedform_79"></a>6</p></td>
<td valign="middle"  style="width:2.56%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-top:3pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;"><a name="fedform_710"></a><a name="fedform_410"></a>&nbsp;</p></td>
<td valign="middle"  style="width:76.14%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:3pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:5.65pt;">
<td colspan="10" valign="middle"  style="width:100%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:3pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;line-height:10pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 &#8211; The articles are amended as follows: <font style="font-family:Arial;">(Note that more than one section can be filled out)</font> </p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;line-height:10pt;margin-left:8.55pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A: The corporation changes its name to:</p></td>
</tr>
<tr style="height:40.15pt;">
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;line-height:10pt;margin-left:8.55pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;"><a name="fedform_411"></a><a name="fedform_411_B"></a><a name="fedform_413"></a><a name="fedform_414"></a><a name="fedform_414_D"></a><a name="fedform_411_D"></a>&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;line-height:10pt;margin-left:8.55pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B: The corporation changes the province or territory in Canada where the registered office is situated to:<br />&nbsp;&nbsp;&nbsp;&nbsp; To complete the change, a Form 3 &#8211; Change of Registered Office Address must accompany the Articles of Amendment.</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;line-height:10pt;margin-left:1.45pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;"><a name="fedform_417"></a><a name="fedform_417_D"></a>&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;line-height:10pt;margin-left:22.7pt;;text-indent:-14.15pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="fedform_419"></a>C: The corporation changes the minimum and/or maximum number of directors to: (for a fixed number of directors, indicate the same number in both boxes).<a name="fedform_419"></a> </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:5.15pt;">
<td rowspan="3" valign="middle"  style="width:19.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="fedform_431"></a>Minimum number</p></td>
<td rowspan="3" valign="middle"  style="width:2.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:3.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td rowspan="3" valign="middle"  style="width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td rowspan="3" valign="middle"  style="width:26.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Maximum number&nbsp;&nbsp;</p></td>
<td valign="middle"  style="width:3.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td rowspan="3" valign="middle"  style="width:33.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:18.6pt;">
<td valign="middle"  style="width:3.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style="width:3.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:14.55pt;">
<td valign="middle"  style="width:3.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:3.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:100%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.7pt;;text-indent:-14.15pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D: Other changes: (for example, to the classes of shares, to restrictions on share transfers, to restrictions on the businesses of the corporation or <br />to any other provisions that are permitted by the CBCA to be set out in the Articles) <font style="font-weight:bold;">Please specify.</font></p></td>
</tr>
<tr style="height:152.95pt;">
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.7pt;;text-indent:-14.15pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.7pt;;text-indent:-14.15pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See attached schedule.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="4" valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;line-height:10pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4 &#8211; Declaration</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I hereby certify that I am a director or an authorized officer of the corporation. </p></td>
</tr>
<tr>
<td valign="top"  style="width:10.24%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature: </p></td>
<td valign="top"  style="width:46.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">/s/ Simon Pimstone</p></td>
<td colspan="2" valign="top"  style="width:43.46%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.24%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print name: </p></td>
<td valign="top"  style="width:46.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Simon Pimstone</p></td>
<td valign="top"  style="width:20.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telephone number:</p></td>
<td valign="top"  style="width:23.22%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">604-484-3302/05</p></td>
</tr>
<tr style="height:6.2pt;">
<td valign="top"  style="width:10.24%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:46.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.24%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:23.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.65pt;;text-indent:-14.2pt;;color:#000000;font-size:8pt;font-family:Arial Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: <font style="font-family:Arial;">Misrepresentation constitutes an offence and, on summary conviction, a person is liable to a fine not exceeding $5000 or to imprisonment for a term not exceeding six months or to both (subsection 250(1) of the CBCA).</font></p></td>
</tr>
</table></div>
<p style="margin-top:6pt;line-height:8pt;margin-bottom:0pt;margin-left:0.45%;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">XENON PHARMACEUTICALS INC. <br /><font style="text-decoration:underline;">ARTICLES OF AMENDMENT</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Paragraph 3 of the Articles of the Corporation shall, pursuant to the <font style="font-style:italic;">Canada Business Corporations Act</font>, be amended as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.7%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.7%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">to designate the first series of preferred shares as Series 1 Preferred shares (the &#8220;<font style="font-weight:bold;">Series 1 Preferred Shares</font>&#8221;), which shall consist of an unlimited number of Series 1 Preferred Shares and in addition to the rights, privileges, restrictions and conditions attaching to all the preferred shares as a class, shall have attached thereto the rights, privileges, restrictions and conditions set out in the annexed Schedule 1; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.7%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.7%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">to declare that the authorized capital of the Corporation, after giving effect to the foregoing, consists of:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.39%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.7%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">an unlimited number of common shares; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.39%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.7%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">an unlimited number of preferred shares, issuable in series, of which an unlimited number have been designated as Series 1 Preferred shares.</p></td></tr></table></div>
<p style="margin-top:6pt;line-height:8pt;margin-bottom:0pt;margin-left:0.45%;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:6pt;line-height:8pt;margin-bottom:0pt;margin-left:0.45%;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">XENON PHARMACEUTICALS INC.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 1</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.7%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref476909981"></a>The rights, privileges, restrictions and conditions attaching to the Series 1 Preferred shares (the &#8220;<font style="font-weight:bold;">Series 1 Preferred Shares</font>&#8221;) are as follows:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.37%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.7%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref476913082"></a><a name="_Ref131914509"></a><a name="_Ref508414180"></a><a name="_Ref508200243"></a><font style="font-weight:bold;">Non-Cumulative Dividends:</font>&#160;Any holder of the Series 1 Preferred Shares (<font style="font-weight:bold;">&#8220;Holder</font><a name="_Ref131914509"></a>&#8221;) will be entitled to receive dividends (other than dividends in the form of Common Shares) on the Series 1 Preferred Shares (without regard to the Beneficial Ownership Limitation (as defined below)) if, as and when declared by the board of directors of the Corporation on the Common Shares out of the assets of the Corporation properly applicable to the payment of dividends in such amounts and payable in such manner as the board of directors of the Corporation may from time to time determine.&#160; However, all dividends which the board of directors of the Corporation may determine to declare and pay in any financial year of the Corporation on the Common Shares must be declared and paid in equal or equivalent amounts per share (calculated on an as-converted basis) on all of the Series 1 Preferred Shares in priority to the holders of the Common Shares. The Corporation shall deliver, or cause to be delivered, to each Holder, at its last address as it shall appear upon the register of securityholders maintained by the Corporation or its transfer agent, a written notice of any dividend at least 10 calendar days prior to the record or effective date of such dividend, stating the date on which a record is to be taken for the purpose of such dividend, or if a record is not to be taken, the date as of which the holders of Common Shares of record to be entitled to such dividend are to be determined.&nbsp;&nbsp;Dividends paid on the Series 1 Preferred Shares will be designated as &#8220;eligible dividends&#8221; in the same proportion as corresponding dividends on the Common Shares designated as &#8220;eligible dividends&#8221; for the purposes of the<font style="font-style:italic;"> Income Tax Act</font><a name="_Ref508414180"></a><a name="_Ref508200243"></a> (Canada).</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.34%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;">Beneficial Ownership Limitation:</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Notwithstanding anything herein to the contrary other than an automatic conversion under Section 1(e), the Corporation shall not effect any conversion of the Series 1 Preferred Shares, and a Holder shall not have the right to convert any portion of the Series 1 Preferred Shares, to the extent that, after giving effect to a proposed conversion set forth on an applicable Notice of Conversion (as defined below) or Option Notice (as defined below), as the case may be, such Holder (together with such Holder&#8217;s affiliates (as such term is defined in the</font><font style="font-style:italic;"> Canada Business Corporations Act</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">), and any other person (as such term is defined in the</font><font style="font-style:italic;"> Canada Business Corporations Act</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) whose beneficial ownership of Common Shares would be aggregated with the Holder&#8217;s for the purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder (the </font><font style="font-weight:bold;">&#8220;Exchange Act</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), and the applicable regulations of the Securities and Exchange Commission (the </font><font style="font-weight:bold;">&#8220;Commission</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) in the United States and National Instrument 62-104</font><font style="font-style:italic;"> Take Over Bids and Issuer Bids </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-weight:bold;">&#8220;NI 62-104</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) in Canada, including any &#8220;group&#8221; of which the Holder is a member (the foregoing, </font><font style="font-weight:bold;">&#8220;Attribution Parties</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)) would beneficially own a number of Common Shares in excess of 9.99% of the number of Common Shares outstanding immediately after giving effect to the issuance of Common Shares pursuant to a Notice of Conversion or Option Notice, as the case may be (the </font><font style="font-weight:bold;">&#8220;Beneficial Ownership Limitation</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), provided, however, that the Holder shall have the right to reset the Beneficial Ownership Limitation to a higher or lower number (not to exceed 19.99% of the number of Common Shares outstanding immediately after giving effect to the issuance of Common Shares pursuant to a Notice of Conversion or Option Notice) upon providing written notice to the Corporation, which notice providing for an increase in the Beneficial Ownership Limitation shall only be effective 61 days after delivery to the Corporation</font><font style="font-weight:bold;">, </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bu</font><font style="font-weight:bold;">t </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no such delay in effectiveness shall be required for a reduction in the Beneficial Ownership Limitation. For purposes of the foregoing sentence, the number of Common Shares beneficially owned by such Holder and its Attribution Parties shall include the number of Common Shares issuable upon conversion of the Series 1 Preferred Shares subject to the Notice of Conversion or Option Notice, as the case may be, with respect to which such determination is being made, but shall exclude the number of Common Shares which are issuable upon (A) conversion of the remaining, unconverted Series 1 Preferred Shares beneficially owned by such Holder or any of its Attribution Parties, and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) where such Common Shares are not deemed to be beneficially owned by the holder under the Exchange Act or NI 62-104. For purposes of this Section 1(b), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the Commission in the United States and NI 62-104 in Canada. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section 13(d) of the Exchange Act and the applicable regulations of the Commission. For purposes of this Section 1(b), in determining the number of outstanding Common Shares, a Holder may rely on the number of outstanding Common Shares as stated in the most recent of the following: (A) the Corporation&#8217;s most recent periodic or annual filing with the Commission, as the case may be; (B) a more recent public announcement by the Corporation that is filed with the Commission; or (C) a more recent notice by the Corporation or the Corporation&#8217;s transfer agent to the Holder setting forth the number of Common Shares then outstanding.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:15.01%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the written request of a Holder, the Corporation shall, within three trading days thereof (which shall mean a day on which the Common Shares are traded for any period on any principal securities exchange, each such day, a (&#8220;<font style="font-weight:bold;">Trading Day</font>&#8221;)), confirm in writing to such Holder the number of Common Shares then outstanding. In any case, the number of outstanding Common Shares shall be determined after giving effect to any actual conversion or exercise of securities of the Corporation, including Series 1 Preferred Shares, by such Holder or its Attribution Parties since the date as of which such number of outstanding Common Shares was last publicly reported or confirmed to the Holder. The Corporation shall be entitled to rely on representations made to it by the Holder in any Notice of Conversion regarding its Beneficial Ownership Limitation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref508731744"></a><br /></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.34%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><a name="_Hlk508392719"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;">Conversion at Holder&#8217;s Option: </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk508392719"></a>Each issued Series 1 Preferred Share may at any time be converted, at the option of the Holder, without payment of any additional consideration, into one Common Share, </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provided that such conversion will not result in such Holder, together with the Attribution Parties, beneficially owning Common Shares in excess of the Beneficial Ownership Limitation</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:15.01%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk508393217"></a><a name="_Hlk508391926"></a><a name="_Hlk508391473"></a><a name="_Hlk508393217"></a>To convert Series 1 Preferred Shares into Common Shares, the Holder shall deliver a form of conversion notice attached hereto as Schedule &#8220;A&#8221; (the &#8220;<font style="font-weight:bold;">Notice of Conversion</font><a name="_Hlk508391926"></a>&#8221;), duly completed and executed, accompanied (either at such time, or as soon as practicable thereafter) by the certificate or certificates for those Series 1 Preferred Shares, duly endorsed, <a name="_Hlk508391473"></a>at the office of the Corporation located at 200 - 3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8, during regular business hours. The Notice of Conversion must specify the number of Series 1 Preferred Shares to be converted, which number shall be at least the lesser of (x) 100,000 Series 1 Preferred Shares (such number subject to appropriate adjustment following the occurrence of another conversion specified herein), (y) the number of Series 1 Preferred Shares then held by the Holder or (z) such other number of Series 1 Preferred Shares as may be agreed to between the Holder and the Corporation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:15.01%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not later than two Trading Days after the Conversion Date (as defined below) (the &#8220;<font style="font-weight:bold;">Share Delivery Date</font>&#8221;), the Corporation shall, at the Holder&#8217;s request, either: (a) deliver, or cause to be delivered, to the converting Holder a physical certificate or certificates representing the number of Common Shares being issued upon the conversion of the Series 1 Preferred Shares, or (b) in the case of a Deposit Withdrawal Commission System (&#8220;<font style="font-weight:bold;">DWAC</font>&#8221;) delivery (&#8220;<font style="font-weight:bold;">DWAC Delivery</font>&#8221;), cause its transfer agent to electronically transfer such Common Shares by crediting the account of the Holder with the Depositary Trust Company (&#8220;<font style="font-weight:bold;">DTC</font>&#8221;) through its DWAC system. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:15.01%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The date on which a conversion shall be deemed effective (the &#8220;<font style="font-weight:bold;">Conversion Date</font>&#8221;) shall be the Trading Day on which the Notice of Conversion is received by the Corporation at the offices of the Corporation located at 200 - 3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8, during regular business hours. In the event the certificates for those Series 1 Preferred Shares being converted, duly endorsed, are not delivered to the Corporation with the Notice of Conversion and the Notice of Conversion is delivered via email to legalaffairs@xenon-pharma.com and investors@xenon-pharma.com or via facsimile at 604-484-3450, during the regular business hours of the Corporation, with such certificates to be received separately by the Corporation at the offices of the Corporation, the conversion shall still be deemed effective on the date of receipt of the Notice of Conversion, and the Series 1 Preferred Shares that shall be deemed to have been surrendered for conversion shall no longer be deemed to be outstanding, any dividends declared but not yet paid in respect of converted Series 1 Preferred Shares shall be paid upon such conversion, and all further rights with respect to such Series 1 Preferred Shares shall immediately cease and terminate (subject to the right of rescission set forth in the following paragraph), except only the right of the holder thereof to receive Common Shares in exchange thereof, as well as dividends and other amounts payable with respect to the Common Shares on or after the Conversion Date. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:15.01%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If, in the case of any Notice of Conversion, such certificate or certificates representing the Common Shares are not delivered to, or in the case of a DWAC Delivery, such Common Shares are not electronically delivered to, the applicable Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for Common Shares or electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return to such Holder any original Series 1 Preferred Share certificate delivered to the Corporation and such Holder shall promptly return to the Corporation any Common Share certificates or otherwise direct the return of any Common Shares delivered to the Holder through the DWAC system, representing the Series 1 Preferred Shares unsuccessfully tendered for conversion to the Corporation.&nbsp;&nbsp;If some but not all Series 1 Preferred Shares represented by a certificate or certificates surrendered by a Holder are converted, the Corporation shall, by no later than the Share Delivery Date or three Trading Days following the Holder&#8217;s delivery of the original Series 1 Preferred Share certificate (whichever is later), issue and deliver to the Holder a new certificate, in such Holder&#8217;s name as shown on such surrendered certificate or certificates, representing the number of Series 1 Preferred Shares which were not converted. All Series 1 Preferred Shares that shall have been surrendered or deemed to have been surrendered for conversion as herein provided shall no longer be deemed to be outstanding, any dividends declared but not yet paid in respect of converted Series 1 Preferred Shares shall be paid upon such conversion, and all further rights with respect to such shares shall immediately cease and terminate, except only the right of the holder thereof to receive Common Shares in exchange thereof.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.34%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref508731746"></a><a name="_Ref508200248"></a><font style="font-weight:bold;">Conversion at Corporation&#8217;s Option:</font>&nbsp;&nbsp;Each issued Series 1 Preferred Share may at any time be converted, at the option of the Corporation, without payment of any additional consideration, into one Common Share, provided that prior to such conversion, the Holder, together with the Attribution Parties, beneficially own less than 5%<font style="font-weight:bold;"> </font>of the issued and outstanding Common Shares (calculated in accordance with Section 1(b)) and the conversion will not result in the Holder, together with the Attribution Parties, beneficially holding more than 5% of the issued and outstanding Common Shares (calculated in accordance with Section 1(b)).&#160;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:15.01%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To convert Series 1 Preferred Shares into Common Shares, the Corporation shall deliver a notice in writing, duly completed, to the Holder in the form attached hereto as Schedule &#8220;B&#8221; (the &#8220;<font style="font-weight:bold;">Option Notice</font>&#8221;), at such Holder&#8217;s last address as it shall appear upon the register of security holders maintained by the Corporation or its transfer agent.&nbsp;&nbsp;The Option Notice shall be delivered at least 30 days prior to the Option Conversion Date (as defined below), unless agreed to otherwise by the Holder, and shall state the date on which the conversion is to take place (the &#8220;<font style="font-weight:bold;">Option Conversion Date</font>&#8221;) and must specify the number of Series 1 Preferred Shares the Corporation wishes to be converted. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:15.01%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not later than the Option Conversion Date (the &#8220;<font style="font-weight:bold;">Option Deadline</font>&#8221;), the Holder shall deliver the Option Notice, duly completed by the Holder, and the certificate or certificates for those Series 1 Preferred Shares being converted, duly endorsed, to the offices of the Corporation located at 200 - 3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8, during regular business hours. Not later than two Trading Days after the Option Conversion Date (the &#8220;<font style="font-weight:bold;">Option Delivery Date</font>&#8221;), the Corporation shall, at the Holder&#8217;s request , either: (a) deliver, or cause to be delivered, to the converting Holder a physical certificate or certificates representing the number of Common Shares being issued upon the conversion of the Series 1 Preferred Shares, or (b) in the case of a DWAC Delivery, cause its transfer agent to electronically transfer such Common Shares by crediting the account of the Holder with DTC through its DWAC system. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:15.01%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event the Option Notice, duly completed by the Holder, and the certificate or certificates for those Series 1 Preferred Shares being converted, duly endorsed, are not delivered by the Holder to the Corporation by the Option Deadline, the conversion shall be deemed to have occurred on the Option Conversion Date and the Series 1 Preferred Shares that shall have been deemed surrendered for conversion shall no longer be deemed to be outstanding, any dividends declared but not yet paid in respect of&nbsp;&nbsp;converted Series 1 Preferred Shares shall be paid upon such conversion, and all further rights with respect to such shares immediately cease and terminate, except only the right of the holder thereof to receive Common Shares in exchange thereof, as well as dividends and other amounts payable with respect to the Common Shares on or after the Option Conversion Date. For greater certainty, the Corporation shall not be required to issue certificates evidencing the Common Shares issuable upon such conversion effected under an Option Notice, or cause its transfer agent to electronically transfer Common Shares to the Holder evidencing the Common Shares issuable upon such conversion effected under an Option Notice, until the certificates formerly evidencing the Series 1 Preferred Shares so converted are delivered to the Corporation as provided for in Section 1(d).</font></p>
<p style="margin-top:12pt;margin-bottom:12pt;margin-left:15.01%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If some but not all Series 1 Preferred Shares represented by a certificate or certificates surrendered by a Holder are converted and the Option Notice, duly completed by the Holder, and the certificate or certificates for those Series 1 Preferred Shares being converted, duly endorsed, are delivered by the Holder to the Corporation by the Option Deadline, the Corporation shall, by no later than the Option Delivery Date, issue and deliver to the Holder, a new certificate, representing the number of Series 1 Preferred Shares which were not converted, in such Holder&#8217;s name as shown on such surrendered certificate or certificates, representing the number of Series 1 Preferred Shares which were not converted.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.34%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;">Automatic Conversion Upon Change of Control:</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;If, at any time while the Series 1 Preferred Shares are outstanding, there should be an acquisition of Common Shares by means of take-over bid, tender offer, exchange offer, amalgamation, merger, acquisition, sale of shares, plan of arrangement or other form of corporate reorganization in which outstanding Common Shares are exchanged for securities or other consideration paid, or caused to be issued or paid, and upon completion of such transaction more than 50% of the voting securities of the Corporation or the reorganized, amalgamated, continuing, merged, surviving or consolidated entity resulting from such transaction are beneficially owned, directly or indirectly, by one or more persons other than persons who beneficially owned more than 50% of the Common Shares (together with, if applicable, other shares of the Corporation that carry a voting right either under all circumstances or under some circumstances that have occurred and are continuing) immediately before the completion of such transaction, other than solely involving the Corporation and one or more of its subsidiaries (a &#8220;</font><font style="font-weight:bold;">Change of Control</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), each Holder shall be issued one Common Share for each Series 1 Preferred Share held by such Holder (together with any accrued but unpaid dividends thereon) immediately prior to the occurrence of such Change of Control, without regard to the Beneficial Ownership Limitation, and following such conversion, the Holder shall be entitled to receive the same kind and amount of securities, cash or property (the &#8220;</font><font style="font-weight:bold;">Alternative Consideration</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) that a holder of Common Shares is entitled to receive. The Corporation shall deliver, or cause to be delivered, to each Holder, at its last address as it shall appear upon the register of securityholders maintained by the Corporation or its transfer agent, written notice of any Change of Control at least 10 calendar days prior to the applicable record or effective date, stating the date on which such Change of Control is expected to become effective or close and the date as of which it is expected that the holders of the Common Shares of record shall be entitled to receive the Alternative Consideration deliverable upon such Change of Control, provided that a failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice on which such Change of Control is expected to become effective or close. All outstanding Series 1 Preferred Shares shall be deemed to be automatically converted on the effective date or closing date of the Change of Control, any dividends declared but not yet paid in respect of such converted Series 1 Preferred Shares shall be paid upon such conversion, and all further rights with respect to such converted Series 1 Preferred Shares shall cease and terminate following such conversion, except only the right of the Holder thereof to receive the Common Shares as herein provided, which Common Shares shall entitle the Holder to receive the Alternative Consideration. </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.34%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref204152832"></a><font style="font-weight:bold;">Payment of Tax Due Upon Issuance:</font><a name="_Ref204152832"></a> The Corporation shall pay any documentary, stamp or similar tax due upon the issuance of Common Shares upon conversion or due upon the issuance of a new certificate for any Series 1 Preferred Shares not converted other than any such tax due because Common Shares or a certificate for Series 1 Preferred Shares are issued in a name other than the name of the converting Holder, which shall be paid by the converting Holder.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref508733503"></a><br /></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.34%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;">Compensation for Buy-In Failure to Timely Deliver Certificates Upon Conversion: </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Corporation fails to deliver to a Holder the applicable certificate or certificates or to effect a DWAC Delivery, as applicable, within three Trading Days from the Conversion Date (other than a failure caused by incorrect or incomplete information provided by Holder to the Corporation) or by the Option Delivery Date pursuant to Section 1(d) (other than a failure of the Holder to deliver the required documents set out in Section 1(d)) and the Holder has not rescinded the applicable Notice of Conversion pursuant to Section 1(c) above, and if after such Share Delivery Date or the Option Delivery Date, as the case may be, such Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise) Common Shares to deliver in satisfaction of a sale by such Holder of the Common Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date or the Option Delivery Date, as the case may be, (a &#8220;</font><font style="font-weight:bold;">Buy-In</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), then the Corporation shall (A) pay in cash to such Holder the amount by which (x) such Holder&#8217;s total purchase price (including any brokerage commissions) for the Common Shares so purchased exceeds (y) the product of (1) the aggregate number of Common Shares that such Holder was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) at the option of such Holder, either reissue (if surrendered) the Series 1 Preferred Shares equal to the number of Series 1 Preferred Shares submitted for conversion or deliver to such Holder the number of Common Shares that would have been issued if the Corporation had timely complied with its delivery requirements under Section 1(c). For example, if a Holder purchases Common Shares having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of Series 1 Preferred Shares with respect to which the actual sale price (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three Trading Days after the occurrence of a Buy-In, indicating the amounts payable to such Holder in respect of such Buy-In, together with applicable confirmations and other evidence reasonably requested by the Corporation. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Corporation&#8217;s failure to timely deliver Common Shares upon conversion of the Series 1 Preferred Shares as required pursuant to the terms hereof; provided, however, that the Holder shall not be entitled to both (i) require the reissuance of the Series 1 Preferred Shares submitted for conversion for which such conversion was not timely honored and (ii) receive the number of Common Shares that would have been issued if the Corporation had timely complied with its delivery requirements under Sections 1(c) or (d). In the event that any payment required to be made to a Holder pursuant to this Section 1(g) is subject to deduction or withholding for or in respect of any taxes, then (a) the amount of any such payment shall be increased as necessary so that after making all required deductions or withholdings (including deductions or withholdings applicable to additional sums payable under this Section 1(g)), the Holder receives an amount equal to the sum it would have received had no such deductions or withholdings been required, (b) the Corporation shall make such deductions or withholdings, and (c) the Corporation shall pay the full amount deducted or withheld to the relevant taxation authority in accordance with applicable law. The Corporation agrees that it will indemnify the Holder for the full amount of any taxes that were required to be withheld or deducted in respect of the aforementioned payments (including, without limitation, any such taxes imposed by any jurisdiction on amounts payable under this Section 1(g)) and any liability (including penalties, interest and expenses) arising therefrom or with respect thereto, whether or not such taxes or other amounts are correctly or legally asserted, and that such indemnification payment shall be made by the Corporation within thirty (30) days from the date that the Holder makes written demand therefor, and the obligations of the Corporation with respect to such indemnification shall survive any conversion or cancellation of the Series 1 Preferred Shares. For greater certainty, any claim for damages under this Section 1(g) shall be limited to actual damages of the Holder and shall not include any consequential or indirect damages whatsoever, and any payments in excess of those required to be made under this Section 1(g) shall be repaid to the Corporation.</font></p></td></tr></table></div>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.34%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;">Shares Fully Paid and Non-Assessable:&nbsp;&nbsp;</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All Common Shares issued upon conversion of the Series 1 Preferred Shares will, upon issuance by the Corporation, be duly and validly issued, as fully paid and non-assessable Common Shares in the capital of the Corporation.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.34%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref509141118"></a><a name="_Ref509257822"></a><font style="font-weight:bold;">Adjustments:</font>&#160; None of the Common Shares may be subdivided, consolidated, reclassified or otherwise changed (a &#8220;<font style="font-weight:bold;">Capital Reorganization</font>&#8221;) unless contemporaneously therewith the Series 1 Preferred Shares are subdivided, consolidated, reclassified or otherwise changed in the same proportion and in the same manner. If Common Shares are exchanged or changed into other securities, cash or other property (such securities, cash or other property, the &#8220;<font style="font-weight:bold;">Reference Property</font>&#8221;) as a result of a transaction, the Series 1 Preferred Shares converted thereafter will be converted into such other securities, cash or other property in the same manner. If such transaction causes the Common Shares to be converted into, or exchanged for the right to receive more than a single type of consideration (determined based in part upon any form of shareholder election), then the Reference Property into which the Series 1 Preferred Shares will be exchangeable shall be deemed to be the weighted average of the types and amounts of consideration received by the holders of Common Shares. The Corporation shall notify the holders of the Series 1 Preferred Shares of such weighted average as soon as practicable after such determination is made. None of the foregoing provisions shall affect the right of a holder of Series 1 Preferred Shares to convert its Series 1 Preferred Shares (i) into Common Shares prior to the effective time of such transaction or (ii) into Reference Property, as applicable, following the effective time of such transaction. The Corporation shall not enter into any agreement for a transaction constituting a Capital Reorganization unless (i) such agreement provides for or does not interfere with or prevent (as applicable) conversion of the Series 1 Preferred Shares into the Reference Property in a manner that is consistent with and gives effect to this Section 1(i), and (ii) to the extent that the Corporation is not the surviving entity in such Capital Reorganization or will be dissolved in connection with such Capital Reorganization, proper provision shall be made in the agreements governing such Capital Reorganization for the conversion of the Series 1 Preferred Shares into Reference Property and, in the case of a Capital Reorganization constituting any sale, lease or other transfer to a third party of the consolidated assets of the Corporation and its subsidiaries substantially as an entirety, an exchange of Series 1 Preferred Shares for the shares of the person to whom the Corporation&#8217;s assets are conveyed or transferred, having voting powers, preferences, and relative, participating, optional or other special rights as nearly equal as possible to those provided herein. The provisions of this Section 1(i) shall similarly apply to successive Capital Reorganization events. If the Corporation, at any time while the Series 1 Preferred Shares are outstanding pays a stock dividend or otherwise makes a distribution or distributions payable in Common Shares, such dividend or distribution shall be applied to the outstanding Series 1 Preferred Shares by the issuance of Series 1 Preferred Shares in the same proportion as the Common Shares.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.34%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;">Common Shares Reserved:</font> For the purpose of effecting the conversion of Series 1 Preferred Shares, the Corporation shall at all times reserve and keep available, free from any pre-emptive rights, out of its treasury or authorized but unissued Common Shares (or Reference Property, to the extent applicable) the full number of Common Shares (or Reference Property, to the extent applicable) deliverable upon the conversion of all outstanding Series 1 Preferred Shares.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(k)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;">Fractional Shares:</font> No fractional Common Shares shall be issued upon conversion of the Series 1 Preferred Shares. All Common Shares (including fractions thereof) issuable upon conversion of more than one Series 1 Preferred Share by a Holder shall be aggregated for purposes of determining whether the conversion would result in the issuance of any fractional share.&nbsp;&nbsp;If, after the aforementioned aggregation, the conversion would result in the issuance of a fraction of a Common Share, the Corporation shall, in lieu of issuing any fractional share, pay the Holder a cash adjustment in respect of such fraction in an amount equal to such fraction multiplied by the Closing Sale Price on the date of conversion. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.34%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(l)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;">Restriction on Transfer of Shares:</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Prior to any sale, transfer or other disposition of Series 1 Preferred Shares, the Holder shall provide the Corporation with prior written notice of the proposed transfer, which shall be provided at least three Trading Days in advance.&nbsp;&nbsp;No transfer may be effected unless the number of Series 1 Preferred Shares being transferred is equal to (or greater than) the lesser of: (x) 100,000 Series 1 Preferred Shares (such number subject to appropriate adjustment following the occurrence of another conversion specified in herein), (y) the number of Series 1 Preferred Shares then held by the Holder or (z) such other number of Series 1 Preferred Shares as may be agreed to between the Holder and the Corporation. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.34%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(m)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;">Participation upon Liquidation, Dissolution or Winding Up:</font>&nbsp;&nbsp;In the event of the liquidation, dissolution or winding up of the Corporation or other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs, the holders of the Series 1 Preferred Shares will be entitled to all property and assets of the Corporation <font style="font-style:italic;">pari passu</font> on a share for share basis with the holders of the Common Shares. The holders of the Series 1 Preferred Shares will be entitled to receive such property and assets of the Corporation prior to the receipt of property and assets of the Corporation by the holders of the Common Shares pursuant to this paragraph.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.34%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(n)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref508733460"></a><font style="font-weight:bold;">Voting Rights:</font>&#160;The Holders will not be entitled to receive notice of or to attend any meeting of the shareholders of the Corporation and will not be entitled to vote at any such meeting. Notwithstanding any provision set out herein, the Corporation shall not, without the affirmative vote of the holders of a majority of the then outstanding Series 1 Preferred Shares, (i) alter or change adversely the powers, preferences or rights given to the Series 1 Preferred Shares herein or alter or amend or repeal any provision of, or add any provision to, the articles or bylaws of the Corporation, or file any articles of amendment, if such action would adversely alter or change the rights, privileges, restrictions and conditions provided for the benefit of the Series 1 Preferred Shares, or (ii) enter into any agreement with respect to any of the foregoing. Notwithstanding the first sentence of this Section 1(n), the Holders shall be entitled to receive notice of and to attend any meeting of the shareholders of the Corporation and vote on all matters on which the Common Shares are entitled to vote, voting together with the holders of the Common Shares on an as-converted basis and as a single class<font style="font-weight:bold;"> </font>provided that the voting rights of any Holder shall not exceed the Beneficial Ownership Limitation then in effect, notwithstanding any voting or other rights the Holder may have at law or otherwise. For the avoidance of doubt, in no case shall a Series 1 Preferred Share be entitled to more than one vote on an as-converted basis. Any Series 1 Preferred Shares that are ineligible to convert into Common Shares due to the Beneficial Ownership Limitation, measured as of a given record date that applies for a shareholder meeting or ability to act by written consent (each, a &#8220;<font style="font-weight:bold;">Record Date</font>&#8221;), shall be deemed to be non-voting securities. In ascertaining the Series 1 Preferred Shares eligible to vote at any special meeting or annual meeting of shareholders, the Corporation shall, prior to a Record Date, seek written confirmation of beneficial ownership and the form of such ownership from each Holder as of the Record Date, whereupon the Holder shall provide a written certification to the Secretary of the Corporation as to such holdings, with the certification to be provided on the business day immediately following such Record Date.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.34%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(o)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;">No Redemption: </font>The Corporation may not redeem any of the Series 1 Preferred Shares.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.34%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(p)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;">Certificates; Lost or Mutilated Series 1 Preferred Shares: </font>If a Holder&#8217;s Series 1 Preferred Share certificate is mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the Series 1 Preferred Shares so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership thereof, satisfactory to the Corporation and, in each case, upon the execution of an indemnity in a form satisfactory to the Corporation indemnifying the Corporation from any loss incurred by it in connection with such certificate and such Holder shall pay such reasonable third-party costs as the Corporation may prescribe.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE A</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOTICE OF CONVERSION</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SERIES 1 PREFERRED SHARES)</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undersigned Holder hereby irrevocably elects to convert the number of Series 1 Preferred Shares of Xenon Pharmaceuticals Inc., a Canadian corporation (the &#8220;<font style="font-weight:bold;">Corporation</font>&#8221;) indicated below, represented by share certificate No(s). &#9679; (the &#8220;<font style="font-weight:bold;">Preferred Shares</font>&#8221;), into common shares of the Corporation (the &#8220;<font style="font-weight:bold;">Common Shares</font>&#8221;), as of the date written below. If securities are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in the schedule of rights, privileges, restrictions and conditions attaching to the Series 1 Preferred Shares (the &#8220;<font style="font-weight:bold;">Series 1 Preferred Share Rights</font>&#8221;). </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the date hereof, the number of Common Shares beneficially owned by the undersigned Holder (together with such Holder&#8217;s affiliates, and any other Person whose beneficial ownership of Common Shares would be aggregated with the Holder&#8217;s for purposes of Section 13(d) or Section 16 of the Exchange Act and the applicable regulations of the Securities and Exchange Commission (the &#8220;<font style="font-weight:bold;">Commission</font>&#8221;)&nbsp;&nbsp;in the United States and National Instrument 62-104 &#8211; <font style="font-style:italic;">Take-Over Bids and Issuer Bids </font>(&#8220;<font style="font-weight:bold;">NI 62-104</font>&#8221;) in Canada, including any &#8220;group&#8221; of which the Holder is a member (the foregoing, &#8220;<font style="font-weight:bold;">Attribution Parties</font>&#8221;)), including the number of Common Shares issuable upon conversion of the Series 1 Preferred Shares subject to this Notice of Conversion, but excluding the number of Common Shares which are issuable upon (A) conversion of the remaining, unconverted Series 1 Preferred Shares beneficially owned by such Holder or any of its Attribution Parties, and (B)<font style="font-weight:bold;"> </font>exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) where such Common Shares are not deemed to be beneficially owned by the holder under the Exchange Act or NI 62-104, is &#9679;%. For purposes hereof, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the Commission in the United States and NI 62-104 in Canada. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section 13(d) of the Exchange Act and the applicable regulations of the Commission in the United States.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date to Effect Conversion: __________________________________</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of Series 1 Preferred Shares owned prior to Conversion: _____________________________</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of Series 1 Preferred Shares to be Converted: ________________________________</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number Common Shares to be Issued: ________________________________</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Address for delivery of physical certificates: __________________________________</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Or </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for DWAC Delivery: _______________________________</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DWAC Instructions:<font style="margin-left:4pt;"></font> ____________________________________</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Account no:<font style="margin-left:4pt;"></font> ___________________________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:53.37%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"></table></div>
<hr style="page-break-after:always;width:100%;">
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="top"  style="width:52.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HOLDER</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:33.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">SCHEDULE B</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OPTION CONVERSION</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SERIES 1<br />PREFERRED SHARES)</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Xenon Pharmaceuticals Inc. (the &#8220;<font style="font-weight:bold;">Corporation</font>&#8221;) hereby irrevocably elects to cause the undersigned Holder to convert &#9679; Series 1 Preferred Shares of the Corporation (the &#8220;<font style="font-weight:bold;">Preferred Shares</font>&#8221;), into common shares of the Corporation (the &#8220;<font style="font-weight:bold;">Common Shares</font>&#8221;), as of the date written below. If securities are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in the schedule of rights, privileges, restrictions and conditions attaching to the Series 1 Preferred Shares (the &#8220;<font style="font-weight:bold;">Series 1 Preferred Share Rights</font>&#8221;). </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the date hereof, the number of Common Shares beneficially owned by the undersigned Holder (together with such Holder&#8217;s affiliates, and any other Person whose beneficial ownership of Common Shares would be aggregated with the Holder&#8217;s for purposes of Section 13(d) or Section 16 of the Exchange Act and the applicable regulations of the Securities and Exchange Commission (the &#8220;<font style="font-weight:bold;">Commission</font>&#8221;) in the United States and National Instrument 62-104 &#8211; <font style="font-style:italic;">Take-Over Bids and Issuer Bids </font>(&#8220;<font style="font-weight:bold;">NI 62-104</font>&#8221;) in Canada, including any &#8220;group&#8221; of which the Holder is a member (the foregoing, &#8220;<font style="font-weight:bold;">Attribution Parties</font>&#8221;)), including the number of Common Shares issuable upon conversion of the Series 1 Preferred Shares subject to this Notice of Conversion, but excluding the number of Common Shares which are issuable upon (A) conversion of the remaining, unconverted Series 1 Preferred Shares beneficially owned by such Holder or any of its Attribution Parties, and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) where such Common Shares are not deemed to be beneficially owned by the holder under the Exchange Act or NI 62-104, is &#9679;%. For purposes hereof, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the Commission in the United States and NI 62-104 in Canada. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section 13(d) of the Exchange Act and the applicable regulations of the Commission in the United States.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date to Effect Conversion: __________________________________</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of Series 1 Preferred Shares owned prior to Conversion: ________________________________</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of Series 1 Preferred Shares to be Converted: ____________________________________</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number Common Shares to be Issued: _______________________________________</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manner of Issuance of Common Shares: ________________________________________</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td colspan="4" valign="top"  style="width:52.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XENON PHARMACEUTICALS INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:26.7%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:18.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:-6.67%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:-6.67%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To be completed by the Holder:</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Address for delivery of physical certificates:<font style="margin-left:4pt;"></font> ___________________________________</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Or</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:6.67%;text-indent:-6.67%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for DWAC Delivery: _____________________________________</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DWAC Instructions:<font style="margin-left:4pt;"></font> __________________________________________</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Account no:<font style="margin-left:4pt;"></font>_______________________________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:-6.67%;font-size:11pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="top"  style="width:52.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HOLDER</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:24.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:20.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;line-height:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>xene-ex41_7.htm
<DESCRIPTION>EX-4.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
xene-ex41_7.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018032803583996429431.jpg" title="" alt="" style="width:864px;height:553px;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;"><br /></font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><img src="g2018032803583998729432.jpg" title="" alt="" style="width:864px;height:564px;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>xene-ex101_6.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
xene-ex101_6.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;"><a name="DocsID"></a>EXCHANGE AGREEMENT</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Exchange Agreement (the &#8220;<font style="font-weight:bold;">Agreement</font>&#8221;), dated as of March 23, 2018 (the &#8220;<font style="font-weight:bold;">Effective Date</font>&#8221;), is entered into by and among Xenon Pharmaceuticals Inc., a Canadian corporation (the &#8220;<font style="font-weight:bold;">Corporation</font>&#8221;), and Biotechnology Value Fund, L.P., a Delaware limited partnership, Biotechnology Value Fund II, L.P., a Delaware limited partnership, Biotechnology Value Trading Fund O.S. L.P., a Cayman Islands limited partnership, Investment 10, L.L.C., an Illinois limited liability company&nbsp;&nbsp;and MSI BVF SPV, L.L.C., a Delaware limited liability company (each a &#8220;<font style="font-weight:bold;">Shareholder</font>&#8221; and, collectively, the &#8220;<font style="font-weight:bold;">Shareholders</font>&#8221; and together, the Corporation and the Shareholders shall be referred to as the &#8220;<font style="font-weight:bold;">Parties</font>&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Corporation is authorized to create and then issue a new series of preferred shares of the Corporation designated as Series 1 Preferred Shares (the &#8220;<font style="font-weight:bold;">Preferred Shares</font>&#8221;), which Preferred Shares shall be convertible into common shares of the Corporation (the &#8220;<font style="font-weight:bold;">Common Shares</font>&#8221;), in accordance with the rights, privileges, conditions and restrictions attached to such Preferred Shares (the &#8220;<font style="font-weight:bold;">Series 1 Preferred Share Rights</font>&#8221;) substantially in the form attached hereto as Schedule &#8220;A&#8221;.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Shareholders and the Corporation wish to exchange that number of Common Shares as set forth next to each Shareholder&#8217;s name in Schedule &#8220;B&#8221; attached hereto (collectively, the &#8220;<font style="font-weight:bold;">Exchanged Shares</font>&#8221;) for that number of Preferred Shares as set forth next to each Shareholder&#8217;s name in Schedule &#8220;B&#8221; attached hereto (the &#8220;<font style="font-weight:bold;">Exchange</font>&#8221;) upon the terms and conditions as set forth herein.&nbsp;&nbsp;The Parties intend that the Exchange of Common Shares for Preferred Shares contemplated herein will be treated as a tax-deferred exchange pursuant to subsection 51(1) of the <font style="font-style:italic;">Income Tax Act </font>(Canada).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Corporation and the Shareholders are executing and delivering this Agreement in reliance upon the exemption from registration afforded by Section 3(a)(9) of the Securities Act of 1933, as amended (the &#8220;1933 Act&#8221;), and the prospectus requirement afforded by BC Instrument 72-503 &#8211; Distribution of Securities Outside British Columbia (&#8220;BCI 72-503&#8221;) as promulgated under the Securities Act (British Columbia) (the &#8220;BCSA&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, the Corporation and the Shareholders hereby agree as follows:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Exchange; Closing.</font> </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to the satisfaction (or waiver) of the conditions set forth herein, on the business day immediately following the filing of the articles of amendment (the &#8220;<font style="font-weight:bold;">Articles of Amendment</font>&#8221;) with the Director (as defined in the <font style="font-style:italic;">Canada Business Corporations Act </font>(&#8220;<font style="font-weight:bold;">CBCA</font>&#8221;)) of Industry Canada to create the Preferred Shares, or such other date as may be agreed to by the Parties (the &#8220;<font style="font-weight:bold;">Closing Date</font>&#8221;), (i) each of the Shareholders shall transfer and assign to the Corporation that number of Exchanged Shares as set forth next to each Shareholder&#8217;s name in Schedule &#8220;B&#8221; attached hereto; (ii) the Corporation shall deliver to each of the Shareholders, to the address set forth next to each Shareholder&#8217;s name in Schedule &#8220;B&#8221; attached hereto, a certificate, registered as directed by such Shareholder, representing the number of Preferred Shares as set forth next to each Shareholder&#8217;s name in Schedule &#8220;B&#8221; attached hereto; and (iii) the Corporation shall irrevocably instruct the Corporation&#8217;s registrar and transfer agent to cancel the direct registration book-entry statements evidencing the Exchanged Shares.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Representations and Warranties of the Corporation</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The Corporation represents, warrants and covenants to, and agrees with, each of the Shareholders as follows: </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Corporation is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with the requisite power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement has been duly executed and delivered by the Corporation, and constitutes the legal, valid and binding obligations of the Corporation, enforceable against the Corporation in accordance with its terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors&#8217; rights and remedies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The execution, delivery and performance of this Agreement by the Corporation and the consummation by the Corporation of the transactions contemplated hereby will not (i) result in a violation of the constating documents of the Corporation; (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Corporation is a party; or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including any applicable securities legislation of each of the provinces and territories of Canada, and the rules, regulations, instruments, notices, blanket orders and policies published and/or promulgated thereunder, as such may be amended from time to time (&#8220;<font style="font-weight:bold;">Applicable Canadian Securities Laws</font>&#8221;)) and the rules and regulations of the NASDAQ Global Market (&#8220;<font style="font-weight:bold;">NASDAQ</font>&#8221;) applicable to the Corporation and, for greater certainty, will be conducted, to the extent applicable, in compliance with Multilateral Instrument 61-101 &#8211; <font style="font-style:italic;">Protection of Minority Securityholders in Special Transactions</font> and National Instrument 62-104 &#8211; <font style="font-style:italic;">Take-Over Bids and Issuer Bids </font>(&#8220;<font style="font-weight:bold;">NI 62-104</font>&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Upon filing the Articles of Amendment with the Director of Industry Canada, the Corporation will be authorized to issue an unlimited number of Preferred Shares. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Corporation will cause to be taken all necessary corporate action to allot and reserve for issuance the Common Shares to be issuable upon conversion of the Preferred Shares without regard to the Beneficial Ownership Limitation (as such term is defined in the <font style="font-weight:bold;"> </font>Series 1 Preferred Share Rights).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither the Corporation, nor any of its affiliates (as such term is defined under United States federal and applicable state securities laws ), nor any person acting on its or their behalf, has paid or given, or agreed to pay or give, directly or indirectly, any commission or other remuneration (within the meaning of Section 3(a)(9) of the 1933 Act and the rules and regulations of the United States Securities and Exchange Commission (the &#8220;<font style="font-weight:bold;">SEC</font>&#8221;) promulgated thereunder) for soliciting the Exchange. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As at the date hereof the Common Shares do not derive, and at no time during the 60-month period preceding the date hereof have the Common Shares derived, more than 50% of their fair market value directly or indirectly from one or any combination of real or immovable property situated in Canada, Canadian resource properties, timber resource properties or options in respect of, or interest in, or civil law rights in, any of the foregoing types of property, whether or not the property exists (as each such term is interpreted for the purposes of the definition of &#8220;taxable Canadian property&#8221; in the <font style="font-style:italic;">Income Tax Act</font> (Canada)).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Representations and Warranties of the Shareholders</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Each Shareholder, as to itself only, represents, warrants and covenants to, and agrees with, the Corporation as follows: </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Shareholder is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with the requisite power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement has been duly executed and delivered by the Shareholder, and constitutes the legal, valid and binding obligations of the Shareholder, enforceable against the Shareholder in accordance with its terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors&#8217; rights and remedies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The execution, delivery and performance of this Agreement by the Shareholder and the consummation by the Shareholder of the transactions contemplated hereby will not (i) result in a violation of the organizational documents of the Shareholder; (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Shareholder is a party; or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to the Shareholder. Notwithstanding the foregoing, for the purposes of this Section 3(c)(iii) with respect to Applicable Canadian Securities Laws, the Shareholder&#8217;s representation is limited solely to any reporting requirements to be complied with by the Shareholder under such laws.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;It is the registered and beneficial owner of, and has valid and marketable title to, that number of Exchanged Shares as set forth next to the Shareholder&#8217;s name in Schedule &#8220;B&#8221; attached hereto, free and clear of any lien, pledge, restriction or other encumbrance (other than restrictions arising pursuant to applicable securities laws), and has the absolute and unrestricted right, power and capacity to transfer and assign to the Corporation such Exchanged Shares being exchanged by it pursuant to this Agreement, free and clear of any lien, pledge, restriction, contractual obligation or other encumbrance. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If a Shareholder is not a United States person, the Shareholder is satisfied as to the full observance of the laws of the Shareholder&#8217;s jurisdiction in connection with Shareholder&#8217;s participation in the Exchange or any use of this Agreement, including (i) the legal requirements within the Shareholder&#8217;s jurisdiction for participation in the Exchange and Shareholder&#8217;s receipt of the Preferred Shares, (ii) any foreign exchange restrictions applicable to such receipt, (iii) any governmental or other consents that may need to be obtained and (iv) the income tax and other tax consequences, if any, that may be relevant to the receipt, holding, redemption, conversion, sale or transfer of such securities. The Shareholder&#8217;s receipt of, and the Shareholder&#8217;s continued beneficial ownership of, the Preferred Shares will not violate any applicable securities or other laws of the Shareholder&#8217;s jurisdiction. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Shareholder (i) is organized in the jurisdiction set forth next to such Shareholder&#8217;s name in Schedule &#8220;B&#8221; attached hereto; (ii) is not resident in, is not located in and does not have an address in, British Columbia or any other province or territory of Canada; and (iii) is acquiring the Preferred Shares as principal.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Shareholder acknowledges and agrees that the Preferred Shares are subject to the rights, privileges, conditions and restrictions contained in the Series 1 Preferred Share Rights attached to such Preferred Shares.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><a name="OLE_LINK1"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK1"></a>The Shareholder understands that the Preferred Shares are being issued to it in reliance on specific exemptions from (i)&#160;the registration requirements of United States federal and applicable state securities laws; and (ii) the </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospectus requirements of Applicable Canadian Securities Laws</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the Province of British Columbia, and that the Corporation is relying upon the truth and accuracy of, and the Shareholder&#8217;s compliance with, the representation in Section 3(f) hereof in order to determine the availability of such exemptions and the eligibility of the Shareholder to acquire the Preferred Shares.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Shareholder acknowledges and agrees that (i)&#160;the Preferred Shares have not been and are not being registered under the 1933 Act or any state securities laws or qualified by prospectus under Applicable Canadian Securities Laws and that the Corporation has no obligation to register or qualify by prospectus the Preferred Shares or the Common Shares issuable upon conversion thereof; (ii) the Preferred Shares are subject to the restrictions on transfer contained in the Series 1 Preferred Share Rights; (iii) there are restrictions under Applicable Canadian Securities Laws on the Shareholder&#8217;s ability to resell the Preferred Shares and the Common Shares issuable upon conversion thereof; and (iv) the Corporation has advised the Shareholder that the Corporation is relying on an exemption from the requirements to provide the Shareholder with a prospectus under Section 3 of BCI 72-503.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither it nor any of its affiliates (as such term is defined under United States federal and applicable state securities laws) nor any person acting on behalf of or for the benefit of any of the foregoing, has paid or given, or agreed to pay or give, directly or indirectly, any commission or other remuneration (within the meaning of Section 3(a)(9) of the 1933 Act and the rules and regulations of the SEC promulgated thereunder) for soliciting the Exchange.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Shareholder is an &#8220;affiliate&#8221; of BVF Partners, L.P., such that any class of voting or equity securities of the Corporation held by the Shareholder are required to be aggregated with voting or equity securities of the same class of the Corporation deemed to be beneficially owned by BVF Partners, L.P., for the purposes of Section 13(d) or Section 16 of the 1933 Act and the applicable regulations of the SEC in the United States and NI 62-104 in Canada.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Shareholder understands that, in addition to any legends required under the Series 1 Preferred Share Rights, the certificates or other instruments representing the Preferred Shares shall bear a legend as set forth below: </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;UNLESS PERMITTED UNDER CANADIAN SECURITIES LEGISLATION, THE HOLDER OF THESE SECURITIES MUST NOT TRADE THE SECURITIES BEFORE [<font style="font-style:italic;">insert date that is four months and a day after the Closing Date</font>].&#8221; </p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Shareholder or the Corporation, as the case may be, exercises their respective right to convert all or any portion of the Preferred Shares held by the Shareholder prior to the date that is four months and a day after the Closing Date in accordance with the provisions of the Series 1 Preferred Share Rights, the Common Shares issuable upon conversion of such Preferred Shares shall bear the same legend set forth above. </p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as expressly provided in this Agreement or otherwise requested or consented to by the Corporation, the Shareholder covenants and agrees to not directly or indirectly sell or otherwise dispose of or transfer any of the Common Shares prior to the Closing Date.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Conditions to the Exchange. </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The obligations of the Parties hereunder to complete the Exchange on the Closing Date is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions may be waived by either Party at any time in its sole discretion by providing the other Party with prior written notice thereof:</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The representations and warranties of the Parties shall be true and correct in all respects&nbsp;&nbsp;as of the date when made and as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date, which shall be true and correct as of such specified date), and the Parties shall have performed, satisfied and complied with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by each Party at or prior to the Closing Date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To the extent applicable, the Corporation shall have obtained the conditional approval of NASDAQ with respect to the consummation of the transactions contemplated by this Agreement; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Corporation shall have filed the Articles of Amendment with the Director of Industry Canada pursuant to this Agreement to create the Preferred Shares substantially in the form attached hereto as Schedule &#8220;A&#8221;.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Miscellaneous.</font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the laws of the Province of British Columbia and the federal laws of Canada applicable therein, without giving effect to any choice of law or conflict of law provision or rule (whether of the Province of British Columbia or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the Province of British Columbia. Each party hereby irrevocably submits to the exclusive jurisdiction of the provincial and federal courts sitting in the City of Vancouver in the Province of British Columbia, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Shareholder shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the Corporation may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Parties acknowledge and agree that the Corporation shall make such filings, announcements, releases or other public disclosure in connection with this Agreement and the transactions contemplated hereby required under applicable corporate and securities laws and rules and regulations of NASDAQ. Notwithstanding the foregoing, no press release or material change report relating to the transactions contemplated hereby may be issued by the Corporation without first obtaining the approval of counsel to the Shareholders. For greater certainty, the Corporation shall not be required to seek approval for any subsequent use of a document approved under this Section 5(c). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMJI5YVt48867AaGp91ny"></a>(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<a name="_9kMJI5YVt48867AaGp91ny"></a>This Agreement represents the entire agreement and understanding among the Parties regarding the terms and conditions of the Exchange and supersedes all prior agreements, arrangements and understandings with respect to the subject matter hereof. This Agreement may only be amended in a written instrument executed by the Parties. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of which, when taken together, shall constitute but one instrument. Delivery of an executed signature page to this Agreement by any Party by electronic transmission shall be as effective as delivery of a manually executed copy of this Agreement by such Party.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement may be terminated by any of the Parties upon written notice if the Closing has not occurred within five business days from the date hereof, provided that the Corporation may not terminate the Agreement pursuant to this Section 5(f) if the failure to close is proximately caused by the Corporation&#8217;s actions (or inaction). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[Signature Page Follows]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><a name="_9kMKJ5YVt48867AaGp91ny"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;"><a name="_9kMKJ5YVt48867AaGp91ny"></a>In witness whereof, the </font><font style="font-weight:normal;">Parties</font><font style="font-weight:normal;"> have executed this Agreement as of the Effective Date. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:46.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="top"  style="width:52.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XENON PHARMACEUTICALS INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:22.64%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">/s/ Ian Mortimer&#160;</p></td>
<td valign="bottom"  style="width:22.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="width:45.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ian Mortimer</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="width:45.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="top"  style="width:52.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XENON PHARMACEUTICALS INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:22.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">/s/ Simon Pimstone&#160;</p></td>
<td valign="bottom"  style="width:22.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="width:44.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Simon Pimstone</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="width:44.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="top"  style="width:52.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times-Bold;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biotechnology Value Fund, L.P.</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:22.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">/s/ Mark Lampert&#160;</p></td>
<td valign="bottom"  style="width:22.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="width:44.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times-Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark Lampert</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="width:44.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President BVF Inc., General Partner of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BVF Partners L.P., itself General Partner of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biotechnology Value Fund, L.P.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="top"  style="width:52.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times-Bold;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biotechnology Value Fund II, L<font style="font-family:TimesNewRomanPS-BoldMT;">.</font>P<font style="font-family:TimesNewRomanPS-BoldMT;">.</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:22.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">/s/ Mark Lampert&#160;</p></td>
<td valign="bottom"  style="width:22.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="width:44.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times-Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark Lampert</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="width:44.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President BVF Inc., General Partner of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BVF Partners L.P., itself General Partner of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biotechnology Value Fund II, L.P.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="top"  style="width:52.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times-Bold;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biotechnology Value Trading Fund OS, L.P.</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:22.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">/s/ Mark Lampert&#160;</p></td>
<td valign="bottom"  style="width:22.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="width:44.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times-Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark Lampert</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="width:44.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President BVF Inc., General Partner of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BVF Partners L.P., itself sole member of BVF</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Partners OS, Ltd., itself General Partner of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biotechnology Value Trading Fund OS, L.P.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="top"  style="width:52.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times-Bold;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment 10, L.L.C.</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:22.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">/s/ Mark Lampert&#160;</p></td>
<td valign="bottom"  style="width:22.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="width:44.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times-Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark Lampert</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="width:44.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President BVF Inc., General Partner of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BVF Partners L.P., itself attorney-in-fact for</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment 10, L.L.C.</p></td>
</tr>
</table></div>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times-Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="top"  style="width:52.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times-Bold;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MSI BVF SPV L.L.C.</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:22.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">/s/ Mark Lampert&#160;</p></td>
<td valign="bottom"  style="width:22.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="width:44.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times-Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark Lampert</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="width:44.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President BVF Inc., General Partner of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BVF Partners L.P., itself attorney-in-fact for MSI BVF SPV L.L.C.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="text-decoration:underline;">Schedule A</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SERIES 1 PREFERRED SHARE RIGHTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(see attached)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">XENON PHARMACEUTICALS INC.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 1</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref476909981"></a>The rights, privileges, restrictions and conditions attaching to the Series 1 Preferred shares (the &#8220;<font style="font-weight:bold;">Series 1 Preferred Shares</font>&#8221;) are as follows:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref476913082"></a><a name="_Ref131914509"></a><font style="font-weight:bold;color:#000000;">Non-Cumulative Dividends:</font><font style="color:#000000;">&#160;Any holder of the Series 1 Preferred Shares (&#8220;</font><font style="font-weight:bold;color:#000000;">Holder</font><font style="color:#000000;"><a name="_Ref131914509"></a>&#8221;) will be entitled to receive dividends (other than dividends in the form of Common Shares) on the Series 1 Preferred Shares (without regard to the Beneficial Ownership Limitation (as defined below)) if, as and when declared by the board of directors of the Corporation on the Common Shares out of the assets of the Corporation properly applicable to the payment of dividends in such amounts and payable in such manner as the board of directors of the Corporation may from time to time determine.&#160; However, all dividends which the board of directors of the Corporation may determine to declare and pay in any financial year of the Corporation on the Common Shares must be declared and paid in equal or equivalent amounts per share (calculated on an as-converted basis) on all of the Series 1 Preferred Shares in priority to the holders of the Common Shares. The Corporation shall deliver, or cause to be delivered, to each Holder, at its last address as it shall appear upon the register of securityholders maintained by the Corporation or its transfer agent, a written notice of any dividend at least 10 calendar days prior to the record or effective date of such dividend, stating the date on which a record is to be taken for the purpose of such dividend, or if a record is not to be taken, the date as of which the holders of Common Shares of record to be entitled to such dividend are to be determined.&nbsp;&nbsp;Dividends paid on the Series 1 Preferred Shares will be designated as &#8220;eligible dividends&#8221; in the same proportion as corresponding dividends on the Common Shares designated as &#8220;eligible dividends&#8221; for the purposes of the </font><font style="font-style:italic;color:#000000;">Income Tax Act</font><font style="color:#000000;"> (Canada).</font></p></td></tr></table></div>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref508414180"></a><a name="_Ref508200243"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;color:#000000;">Beneficial Ownership Limitation:</font><font style="color:#000000;"> Notwithstanding anything herein to the contrary other than an automatic conversion under Section 1(e), the Corporation shall not effect any conversion of the Series 1 Preferred Shares, and a Holder shall not have the right to convert any portion of the Series 1 Preferred Shares, to the extent that, after giving effect to a proposed conversion set forth on an applicable Notice of Conversion (as defined below) or Option Notice (as defined below), as the case may be, such Holder (together with such Holder&#8217;s affiliates (as such term is defined in the </font><font style="font-style:italic;color:#000000;">Canada Business Corporations Act</font><font style="color:#000000;">), and any other person (as such term is defined in the </font><font style="font-style:italic;color:#000000;">Canada Business Corporations Act</font><font style="color:#000000;">) whose beneficial ownership of Common Shares would be aggregated with the Holder&#8217;s for the purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder (the &#8220;</font><font style="font-weight:bold;color:#000000;">Exchange Act</font><font style="color:#000000;">&#8221;), and the applicable regulations of the Securities and Exchange Commission (the &#8220;</font><font style="font-weight:bold;color:#000000;">Commission</font><font style="color:#000000;">&#8221;) in the United States and National Instrument 62-104 </font><font style="font-style:italic;color:#000000;">Take Over Bids and Issuer Bids </font><font style="color:#000000;">(&#8220;</font><font style="font-weight:bold;color:#000000;">NI 62-104</font><font style="color:#000000;">&#8221;) in Canada, including any &#8220;group&#8221; of which the Holder is a member (the foregoing, &#8220;</font><font style="font-weight:bold;color:#000000;">Attribution Parties</font><font style="color:#000000;">&#8221;)) would beneficially own a number of Common Shares in excess of 9.99% of the number of Common Shares outstanding immediately after giving effect to the issuance of Common Shares pursuant to a Notice of Conversion or Option Notice, as the case may be (the &#8220;</font><font style="font-weight:bold;color:#000000;">Beneficial Ownership Limitation</font><font style="color:#000000;">&#8221;), provided, however, that the Holder shall have the right to reset the Beneficial Ownership Limitation to a higher or lower number (not to exceed 19.99% of the number of Common Shares outstanding immediately after giving effect to the issuance of Common Shares pursuant to a Notice of Conversion or Option Notice) upon providing written notice to the Corporation, which notice providing for an increase in the Beneficial Ownership Limitation shall only be effective 61 days after delivery to the Corporation,</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">but</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">no such delay in effectiveness shall be required for a reduction in the Beneficial Ownership Limitation. For purposes of the foregoing sentence, the number of Common Shares beneficially owned by such Holder and its Attribution Parties shall include the number of Common Shares issuable upon conversion of the Series 1 Preferred Shares subject to the Notice of Conversion or Option Notice, as the case may be, with respect to which such determination is being made, but shall exclude the number of Common Shares which are issuable upon (A) conversion of the remaining, unconverted Series 1 Preferred Shares beneficially owned by such Holder or any of its Attribution Parties, and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) where such Common Shares are not deemed to be beneficially owned by the holder under the Exchange Act or NI 62-104. For purposes of this Section 1(b), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the Commission in the United States and NI 62-104 in Canada. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section 13(d) of the Exchange Act and the applicable regulations of the Commission. For purposes of this Section 1(b), in determining the number of outstanding Common Shares, a Holder may rely on the number of outstanding Common Shares as stated in the most recent of the following: (A) the Corporation&#8217;s most recent periodic or annual filing with the Commission, as the case may be; (B) a more recent public announcement by the Corporation that is filed with the Commission; or (C) a more recent notice by the Corporation or the Corporation&#8217;s transfer agent to the Holder setting forth the number of Common Shares then outstanding.</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the written request of a Holder, the Corporation shall, within three trading days thereof (which shall mean a day on which the Common Shares are traded for any period on any principal securities exchange, each such day, a (&#8220;</font><font style="font-weight:bold;">Trading Day</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)), confirm in writing to such Holder the number of Common Shares then outstanding. In any case, the number of outstanding Common Shares shall be determined after giving effect to any actual conversion or exercise of securities of the Corporation, including Series 1 Preferred Shares, by such Holder or its Attribution Parties since the date as of which such number of outstanding Common Shares was last publicly reported or confirmed to the Holder. The Corporation shall be entitled to rely on representations made to it by the Holder in any Notice of Conversion regarding its Beneficial Ownership Limitation.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref508731744"></a><a name="_Hlk508392719"></a><font style="font-weight:bold;color:#000000;">Conversion at Holder&#8217;s Option: </font><font style="color:#000000;"><a name="_Hlk508392719"></a>Each issued Series 1 Preferred Share may at any time be converted, at the option of the Holder, without payment of any additional consideration, into one Common Share, provided that such conversion will not result in such Holder, together with the Attribution Parties, beneficially owning Common Shares in excess of the Beneficial Ownership Limitation.&#160;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk508393217"></a><a name="_Hlk508391926"></a><a name="_Hlk508391473"></a><a name="_Hlk508393217"></a>To convert Series 1 Preferred Shares into Common Shares, the Holder shall deliver a form of conversion notice attached hereto as Schedule &#8220;A&#8221; (the &#8220;<font style="font-weight:bold;">Notice of Conversion</font><a name="_Hlk508391926"></a>&#8221;), duly completed and executed, accompanied (either at such time, or as soon as practicable thereafter) by the certificate or certificates for those Series 1 Preferred Shares, duly endorsed, <a name="_Hlk508391473"></a>at the office of the Corporation located at 200 - 3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8, during regular business hours. The Notice of Conversion must specify the number of Series 1 Preferred Shares to be converted, which number shall be at least the lesser of (x) 100,000 Series 1 Preferred Shares (such number subject to appropriate adjustment following the occurrence of another conversion specified herein), (y) the number of Series 1 Preferred Shares then held by the Holder or (z) such other number of Series 1 Preferred Shares as may be agreed to between the Holder and the Corporation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not later than two Trading Days after the Conversion Date (as defined below) (the &#8220;<font style="font-weight:bold;">Share Delivery Date</font>&#8221;), the Corporation shall, at the Holder&#8217;s request, either: (a) deliver, or cause to be delivered, to the converting Holder a physical certificate or certificates representing the number of Common Shares being issued upon the conversion of the Series 1 Preferred Shares, or (b) in the case of a Deposit Withdrawal Commission System (&#8220;<font style="font-weight:bold;">DWAC</font>&#8221;) delivery (&#8220;<font style="font-weight:bold;">DWAC Delivery</font>&#8221;), cause its transfer agent to electronically transfer such Common Shares by crediting the account of the Holder with the Depositary Trust Company (&#8220;<font style="font-weight:bold;">DTC</font>&#8221;) through its DWAC system. </p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The date on which a conversion shall be deemed effective (the &#8220;</font><font style="font-weight:bold;">Conversion Date</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) shall be the Trading Day on which the Notice of Conversion is received by the Corporation at the offices of the Corporation located at 200 - 3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8, during regular business hours. In the event the certificates for those Series 1 Preferred Shares being converted, duly endorsed, are not delivered to the Corporation with the Notice of Conversion and the Notice of Conversion is delivered via email to legalaffairs@xenon-pharma.com and investors@xenon-pharma.com or via facsimile at 604-484-3450, during the regular business hours of the Corporation, with such certificates to be received separately by the Corporation at the offices of the Corporation, the conversion shall still be deemed effective on the date of receipt of the Notice of Conversion, and the Series 1 Preferred Shares that shall be deemed to have been surrendered for conversion shall no longer be deemed to be outstanding, any dividends declared but not yet paid in respect of converted Series 1 Preferred Shares shall be paid upon such conversion, and all further rights with respect to such Series 1 Preferred Shares shall immediately cease and terminate (subject to the right of rescission set forth in the following paragraph), except only the right of the holder thereof to receive Common Shares in exchange thereof, as well as dividends and other amounts payable with respect to the Common Shares on or after the Conversion Date. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If, in the case of any Notice of Conversion, such certificate or certificates representing the Common Shares are not delivered to, or in the case of a DWAC Delivery, such Common Shares are not electronically delivered to, the applicable Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for Common Shares or electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return to such Holder any original Series 1 Preferred Share certificate delivered to the Corporation and such Holder shall promptly return to the Corporation any Common Share certificates or otherwise direct the return of any Common Shares delivered to the Holder through the DWAC system, representing the Series 1 Preferred Shares unsuccessfully tendered for conversion to the Corporation.&nbsp;&nbsp;If some but not all Series 1 Preferred Shares represented by a certificate or certificates surrendered by a Holder are converted, the Corporation shall, by no later than the Share Delivery Date or three Trading Days following the Holder&#8217;s delivery of the original Series 1 Preferred Share certificate (whichever is later), issue and deliver to the Holder a new certificate, in such Holder&#8217;s name as shown on such surrendered certificate or certificates, representing the number of Series 1 Preferred Shares which were not converted. All Series 1 Preferred Shares that shall have been surrendered or deemed to have been surrendered for conversion as herein provided shall no longer be deemed to be outstanding, any dividends declared but not yet paid in respect of converted Series 1 Preferred Shares shall be paid upon such conversion, and all further rights with respect to such shares shall immediately cease and terminate, except only the right of the holder thereof to receive Common Shares in exchange thereof.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref508731746"></a><a name="_Ref508200248"></a><font style="font-weight:bold;color:#000000;">Conversion at Corporation&#8217;s Option:</font><font style="color:#000000;">&nbsp;&nbsp;Each issued Series 1 Preferred Share may at any time be converted, at the option of the Corporation, without payment of any additional consideration, into one Common Share, provided that prior to such conversion, the Holder, together with the Attribution Parties, beneficially own less than 5%</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">of the issued and outstanding Common Shares (calculated in accordance with Section 1(b)) and the conversion will not result in the Holder, together with the Attribution Parties, beneficially holding more than 5% of the issued and outstanding Common Shares (calculated in accordance with Section 1(b)).&#160;</font></p></td></tr></table></div>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To convert Series 1 Preferred Shares into Common Shares, the Corporation shall deliver a notice in writing, duly completed, to the Holder in the form attached hereto as Schedule &#8220;B&#8221; (the &#8220;</font><font style="font-weight:bold;">Option Notice</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), at such Holder&#8217;s last address as it shall appear upon the register of security holders maintained by the Corporation or its transfer agent.&nbsp;&nbsp;The Option Notice shall be delivered at least 30 days prior to the Option Conversion Date (as defined below), unless agreed to otherwise by the Holder, and shall state the date on which the conversion is to take place (the &#8220;</font><font style="font-weight:bold;">Option Conversion Date</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) and must specify the number of Series 1 Preferred Shares the Corporation wishes to be converted. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not later than the Option Conversion Date (the &#8220;<font style="font-weight:bold;">Option Deadline</font>&#8221;), the Holder shall deliver the Option Notice, duly completed by the Holder, and the certificate or certificates for those Series 1 Preferred Shares being converted, duly endorsed, to the offices of the Corporation located at 200 - 3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8, during regular business hours. Not later than two Trading Days after the Option Conversion Date (the &#8220;<font style="font-weight:bold;">Option Delivery Date</font>&#8221;), the Corporation shall, at the Holder&#8217;s request , either: (a) deliver, or cause to be delivered, to the converting Holder a physical certificate or certificates representing the number of Common Shares being issued upon the conversion of the Series 1 Preferred Shares, or (b) in the case of a DWAC Delivery, cause its transfer agent to electronically transfer such Common Shares by crediting the account of the Holder with DTC through its DWAC system. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event the Option Notice, duly completed by the Holder, and the certificate or certificates for those Series 1 Preferred Shares being converted, duly endorsed, are not delivered by the Holder to the Corporation by the Option Deadline, the conversion shall be deemed to have occurred on the Option Conversion Date and the Series 1 Preferred Shares that shall have been deemed surrendered for conversion shall no longer be deemed to be outstanding, any dividends declared but not yet paid in respect of&nbsp;&nbsp;converted Series 1 Preferred Shares shall be paid upon such conversion, and all further rights with respect to such shares immediately cease and terminate, except only the right of the holder thereof to receive Common Shares in exchange thereof, as well as dividends and other amounts payable with respect to the Common Shares on or after the Option Conversion Date. For greater certainty, the Corporation shall not be required to issue certificates evidencing the Common Shares issuable upon such conversion effected under an Option Notice, or cause its transfer agent to electronically transfer Common Shares to the Holder evidencing the Common Shares issuable upon such conversion effected under an Option Notice, until the certificates formerly evidencing the Series 1 Preferred Shares so converted are delivered to the Corporation as provided for in Section 1(d).</p>
<p style="margin-top:12pt;margin-bottom:12pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If some but not all Series 1 Preferred Shares represented by a certificate or certificates surrendered by a Holder are converted and the Option Notice, duly completed by the Holder, and the certificate or certificates for those Series 1 Preferred Shares being converted, duly endorsed, are delivered by the Holder to the Corporation by the Option Deadline, the Corporation shall, by no later than the Option Delivery Date, issue and deliver to the Holder, a new certificate, representing the number of Series 1 Preferred Shares which were not converted, in such Holder&#8217;s name as shown on such surrendered certificate or certificates, representing the number of Series 1 Preferred Shares which were not converted.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;color:#000000;">Automatic Conversion Upon Change of Control:</font><font style="color:#000000;">&nbsp;&nbsp;If, at any time while the Series 1 Preferred Shares are outstanding, there should be an acquisition of Common Shares by means of take-over bid, tender offer, exchange offer, amalgamation, merger, acquisition, sale of shares, plan of arrangement or other form of corporate reorganization in which outstanding Common Shares are exchanged for securities or other consideration paid, or caused to be issued or paid, and upon completion of such transaction more than 50% of the voting securities of the Corporation or the reorganized, amalgamated, continuing, merged, surviving or consolidated entity resulting from such transaction are beneficially owned, directly or indirectly, by one or more persons other than persons who beneficially owned more than 50% of the Common Shares (together with, if applicable, other shares of the Corporation that carry a voting right either under all circumstances or under some circumstances that have occurred and are continuing) immediately before the completion of such transaction, other than solely involving the Corporation and one or more of its subsidiaries (a &#8220;</font><font style="font-weight:bold;color:#000000;">Change of Control</font><font style="color:#000000;">&#8221;), each Holder shall be issued one Common Share for each Series 1 Preferred Share held by such Holder (together with any accrued but unpaid dividends thereon) immediately prior to the occurrence of such Change of Control, without regard to the Beneficial Ownership Limitation, and following such conversion, the Holder shall be entitled to receive the same kind and amount of securities, cash or property (the &#8220;</font><font style="font-weight:bold;color:#000000;">Alternative Consideration</font><font style="color:#000000;">&#8221;) that a holder of Common Shares is entitled to receive. The Corporation shall deliver, or cause to be delivered, to each Holder, at its last address as it shall appear upon the register of securityholders maintained by the Corporation or its transfer agent, written notice of any Change of Control at least 10 calendar days prior to the applicable record or effective date, stating the date on which such Change of Control is expected to become effective or close and the date as of which it is expected that the holders of the Common Shares of record shall be entitled to receive the Alternative Consideration deliverable upon such Change of Control, provided that a failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice on which such Change of Control is expected to become effective or close. All outstanding Series 1 Preferred Shares shall be deemed to be automatically converted on the effective date or closing date of the Change of Control, any dividends declared but not yet paid in respect of such converted Series 1 Preferred Shares shall be paid upon such conversion, and all further rights with respect to such converted Series 1 Preferred Shares shall cease and terminate following such conversion, except only the right of the Holder thereof to receive the Common Shares as herein provided, which Common Shares shall entitle the Holder to receive t</font><font style="color:#000000;">he Alternative Consideration.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:12pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref204152832"></a><font style="font-weight:bold;color:#000000;">Payment of Tax Due Upon Issuance:</font><font style="color:#000000;"><a name="_Ref204152832"></a> The Corporation shall pay any documentary, stamp or similar tax due upon the issuance of Common Shares upon conversion or due upon the issuance of a new certificate for any Series 1 Preferred Shares not converted other than any such tax due because Common Shares or a certificate for Series 1 Preferred Shares are issued in a name other than the name of the converting Holder, which shall be paid by the converting Holder.</font></p></td></tr></table></div>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref508733503"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:12pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;color:#000000;">Compensation for Buy-In Failure to Timely Deliver Certificates Upon Conversion: </font><font style="color:#000000;">If the Corporation fails to deliver to a Holder the applicable certificate or certificates or to effect a DWAC Delivery, as applicable, within three Trading Days from the Conversion Date (other than a failure caused by incorrect or incomplete information provided by Holder to the Corporation) or by the Option Delivery Date pursuant to Section 1(d) (other than a failure of the Holder to deliver the required documents set out in Section 1(d)) and the Holder has not rescinded the applicable Notice of Conversion pursuant to Section 1(c) above, and if after such Share Delivery Date or the Option Delivery Date, as the case may be, such Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise) Common Shares to deliver in satisfaction of a sale by such Holder of the Common Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date or the Option Delivery Date, as the case may be, (a &#8220;</font><font style="font-weight:bold;color:#000000;">Buy-In</font><font style="color:#000000;">&#8221;), then the Corporation shall (A) pay in cash to such Holder the amount by which (x) such Holder&#8217;s total purchase price (including any brokerage commissions) for the Common Shares so purchased exceeds (y) the product of (1) the aggregate number of Common Shares that such Holder was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) at the option of such Holder, either reissue (if surrendered) the Series 1 Preferred Shares equal to the number of Series 1 Preferred Shares submitted for conversion or deliver to such Holder the number of Common Shares that would have been issued if the Corporation had timely complied with its delivery requirements under Section 1(c). For example, if a Holder purchases Common Shares having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of Series 1 Preferred Shares with respect to which the actual sale price (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three Trading Days after the occurrence of a Buy-In, indicating the amounts payable to such Holder in respect of such Buy-In, together with applicable confirmations and other evidence reasonably requested by the Corporation. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Corporation&#8217;s failure to timely deliver Common Shares upon conversion of the Series 1 Preferred Shares as required pursuant to the terms hereof; provided, however, that the Holder shall not be entitled to both (i) require the reissuance of the Series 1 Preferred Shares submitted for conversion for which such conversion was not timely honored and (ii) receive the number of Common Shares that would have been issued if the Corporation had timely complied with its delivery requirements under Sections 1(c) or (d). In the event that any payment required to be made to a Holder pursuant to this Section 1(g) is subject to deduction or withholding for or in respect of any taxes, then (a) the amount of any such payment shall be increased as necessary so that after making all required deductions or withholdings (including deductions or withholdings applicable to additional sums payable under this Section 1(g)), the Holder receives an amount equal to the sum it would have received had no such deductions or withholdings been required, (b) the Corporation shall make such deductions or withholdings, and (c) the Corporation shall pay the full amount deducted or withheld to the relevant taxation authority in accordance with applicable law. The Corporation agrees that it will indemnify the Holder for the full amount of any taxes that were required to be withheld or deducted in respect of the aforementioned payments (including, without limitation, any such taxes imposed by any jurisdiction on amounts payable under this Section 1(g)) and any liability (including penalties, interest and expenses) arising therefrom or with respect thereto, whether or not such taxes or other amounts are correctly or legally asserted, and that such indemnification payment shall be made by the Corporation within thirty (30) days from the date that the Holder makes written demand therefor, and the obligations of the Corporation with respect to such indemnification shall survive any conversion or </font><font style="color:#000000;">cancellation of the Series 1 Preferred Shares. For greater certainty, any claim for damages under this Section 1(g) shall be limited to actual damages of the Holder and shall not include any consequential or indirect damages whatsoever, and any payments in excess of those required to be made under this Section 1(g) shall be repaid to the Corporation.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Shares Fully Paid and Non-Assessable:&nbsp;&nbsp;</font><font style="color:#000000;">All Common Shares issued upon conversion of the Series 1 Preferred Shares will, upon issuance by the Corporation, be duly and validly issued, as fully paid and non-assessable Common Shares in the capital of the Corporation.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref509141118"></a><a name="_Ref509257822"></a><font style="font-weight:bold;color:#000000;">Adjustments:</font><font style="color:#000000;">&#160; None of the Common Shares may be subdivided, consolidated, reclassified or otherwise changed (a &#8220;</font><font style="font-weight:bold;color:#000000;">Capital Reorganization</font><font style="color:#000000;">&#8221;) unless contemporaneously therewith the Series 1 Preferred Shares are subdivided, consolidated, reclassified or otherwise changed in the same proportion and in the same manner. If Common Shares are exchanged or changed into other securities, cash or other property (such securities, cash or other property, the &#8220;</font><font style="font-weight:bold;color:#000000;">Reference Property</font><font style="color:#000000;">&#8221;) as a result of a transaction, the Series 1 Preferred Shares converted thereafter will be converted into such other securities, cash or other property in the same manner. If such transaction causes the Common Shares to be converted into, or exchanged for the right to receive more than a single type of consideration (determined based in part upon any form of shareholder election), then the Reference Property into which the Series 1 Preferred Shares will be exchangeable shall be deemed to be the weighted average of the types and amounts of consideration received by the holders of Common Shares. The Corporation shall notify the holders of the Series 1 Preferred Shares of such weighted average as soon as practicable after such determination is made. None of the foregoing provisions shall affect the right of a holder of Series 1 Preferred Shares to convert its Series 1 Preferred Shares (i) into Common Shares prior to the effective time of such transaction or (ii) into Reference Property, as applicable, following the effective time of such transaction. The Corporation shall not enter into any agreement for a transaction constituting a Capital Reorganization unless (i) such agreement provides for or does not interfere with or prevent (as applicable) conversion of the Series 1 Preferred Shares into the Reference Property in a manner that is consistent with and gives effect to this Section 1(i), and (ii) to the extent that the Corporation is not the surviving entity in such Capital Reorganization or will be dissolved in connection with such Capital Reorganization, proper provision shall be made in the agreements governing such Capital Reorganization for the conversion of the Series 1 Preferred Shares into Reference Property and, in the case of a Capital Reorganization constituting any sale, lease or other transfer to a third party of the consolidated assets of the Corporation and its subsidiaries substantially as an entirety, an exchange of Series 1 Preferred Shares for the shares of the person to whom the Corporation&#8217;s assets are conveyed or transferred, having voting powers, preferences, and relative, participating, optional or other special rights as nearly equal as possible to those provided herein. The provisions of this Section 1(i) shall similarly apply to successive Capital Reorganization events. If the Corporation, at any time while the Series 1 Preferred Shares are outstanding pays a stock dividend or otherwise makes a distribution or distributions payable in Common Shares, such dividend or distribution shall be applied to the outstanding Series 1 Preferred Shares by the issuance of Series 1 Preferred Shares in the same proportion as the Common Shares.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Common Shares Reserved:</font><font style="color:#000000;"> For the purpose of effecting the conversion of Series 1 Preferred Shares, the Corporation shall at all times reserve and keep available, free from any pre-emptive rights, out of its treasury or authorized but unissued Common Shares (or Reference Property, to the extent applicable) the full number of Common Shares (or Reference Property, to the extent applicable) deliverable upon the conversion of all outstanding Series 1 Preferred Shares.</font></p></td></tr></table></div>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(k)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;color:#000000;">Fractional Shares:</font><font style="color:#000000;"> No fractional Common Shares shall be issued upon conversion of the Series 1 Preferred Shares. All Common Shares (including fractions thereof) issuable upon conversion of more than one Series 1 Preferred Share by a Holder shall be aggregated for purposes of determining whether the conversion would result in the issuance of any fractional share.&nbsp;&nbsp;If, after the aforementioned aggregation, the conversion would result in the issuance of a fraction of a Common Share, the Corporation shall, in lieu of issuing any fractional share, pay the Holder a cash adjustment in respect of such fraction in an amount equal to such fraction multiplied by the Closing Sale Price on the date of conversion. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(l)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Restriction on Transfer of Shares:</font><font style="color:#000000;"> Prior to any sale, transfer or other disposition of Series 1 Preferred Shares, the Holder shall provide the Corporation with prior written notice of the proposed transfer, which shall be provided at least three Trading Days in advance.&nbsp;&nbsp;No transfer may be effected unless the number of Series 1 Preferred Shares being transferred is equal to (or greater than) the lesser of: (x) 100,000 Series 1 Preferred Shares (such number subject to appropriate adjustment following the occurrence of another conversion specified in herein), (y) the number of Series 1 Preferred Shares then held by the Holder or (z) such other number of Series 1 Preferred Shares as may be agreed to between the Holder and the Corporation. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(m)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Participation upon Liquidation, Dissolution or Winding Up:</font><font style="color:#000000;">&nbsp;&nbsp;In the event of the liquidation, dissolution or winding up of the Corporation or other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs, the holders of the Series 1 Preferred Shares will be entitled to all property and assets of the Corporation </font><font style="font-style:italic;color:#000000;">pari passu</font><font style="color:#000000;"> on a share for share basis with the holders of the Common Shares. The holders of the Series 1 Preferred Shares will be entitled to receive such property and assets of the Corporation prior to the receipt of property and assets of the Corporation by the holders of the Common Shares pursuant to this paragraph.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(n)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref508733460"></a><font style="font-weight:bold;color:#000000;">Voting Rights:</font><font style="color:#000000;">&#160;The Holders will not be entitled to receive notice of or to attend any meeting of the shareholders of the Corporation and will not be entitled to vote at any such meeting. Notwithstanding any provision set out herein, the Corporation shall not, without the affirmative vote of the holders of a majority of the then outstanding Series 1 Preferred Shares, (i) alter or change adversely the powers, preferences or rights given to the Series 1 Preferred Shares herein or alter or amend or repeal any provision of, or add any provision to, the articles or bylaws of the Corporation, or file any articles of amendment, if such action would adversely alter or change the rights, privileges, restrictions and conditions provided for the benefit of the Series 1 Preferred Shares, or (ii) enter into any agreement with respect to any of the foregoing. Notwithstanding the first sentence of this Section 1(n), the Holders shall be entitled to receive notice of and to attend any meeting of the shareholders of the Corporation and vote on all matters on which the Common Shares are entitled to vote, voting together with the holders of the Common Shares on an as-converted basis and as a single class</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">provided that the voting rights of any Holder shall not exceed the Beneficial Ownership Limitation then in effect, notwithstanding any voting or other rights the Holder may have at law or otherwise. For the avoidance of doubt, in no case shall a Series 1 Preferred Share be entitled to more than one vote on an as-converted basis. Any Series 1 Preferred Shares that are ineligible to convert into Common Shares due to the Beneficial Ownership Limitation, measured as of a given record date that applies for a shareholder meeting or ability to act by written consent (each, a &#8220;</font><font style="font-weight:bold;color:#000000;">Record Date</font><font style="color:#000000;">&#8221;), shall be deemed to be non-voting securities. In ascertaining the Series 1 Preferred Shares eligible to vote at any special meeting or annual meeting of shareholders, the Corporation shall, prior to a Record Date, seek written confirmation of beneficial ownership and the form of such ownership from each Holder as of the Record Date, whereupon the Holder shall provide a written certification to the Secretary of the Corporation as to such holdings, with the certification to be provided on the business day immediately following such Record Date.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(o)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;color:#000000;">No Redemption: </font><font style="color:#000000;">The Corporation may not redeem any of the Series 1 Preferred Shares.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(p)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;color:#000000;">Certificates; Lost or Mutilated Series 1 Preferred Shares: </font><font style="color:#000000;">If a Holder&#8217;s Series 1 Preferred Share certificate is mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the Series 1 Preferred Shares so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership thereof, satisfactory to the Corporation and, in each case, upon the execution of an indemnity in a form satisfactory to the Corporation indemnifying the Corporation from any loss incurred by it in connection with such certificate and such Holder shall pay such reasonable third-party costs as the Corporation may prescribe.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE A</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOTICE OF CONVERSION</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SERIES 1 PREFERRED SHARES)</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undersigned Holder hereby irrevocably elects to convert the number of Series 1 Preferred Shares of Xenon Pharmaceuticals Inc., a Canadian corporation (the &#8220;<font style="font-weight:bold;">Corporation</font>&#8221;) indicated below, represented by share certificate No(s). &#9679; (the &#8220;<font style="font-weight:bold;">Preferred Shares</font>&#8221;), into common shares of the Corporation (the &#8220;<font style="font-weight:bold;">Common Shares</font>&#8221;), as of the date written below. If securities are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in the schedule of rights, privileges, restrictions and conditions attaching to the Series 1 Preferred Shares (the &#8220;<font style="font-weight:bold;">Series 1 Preferred Share Rights</font>&#8221;). </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the date hereof, the number of Common Shares beneficially owned by the undersigned Holder (together with such Holder&#8217;s affiliates, and any other Person whose beneficial ownership of Common Shares would be aggregated with the Holder&#8217;s for purposes of Section 13(d) or Section 16 of the Exchange Act and the applicable regulations of the Securities and Exchange Commission (the &#8220;<font style="font-weight:bold;">Commission</font>&#8221;)&nbsp;&nbsp;in the United States and National Instrument 62-104 &#8211; <font style="font-style:italic;">Take-Over Bids and Issuer Bids </font>(&#8220;<font style="font-weight:bold;">NI 62-104</font>&#8221;) in Canada, including any &#8220;group&#8221; of which the Holder is a member (the foregoing, &#8220;<font style="font-weight:bold;">Attribution Parties</font>&#8221;)), including the number of Common Shares issuable upon conversion of the Series 1 Preferred Shares subject to this Notice of Conversion, but excluding the number of Common Shares which are issuable upon (A) conversion of the remaining, unconverted Series 1 Preferred Shares beneficially owned by such Holder or any of its Attribution Parties, and (B)<font style="font-weight:bold;"> </font>exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) where such Common Shares are not deemed to be beneficially owned by the holder under the Exchange Act or NI 62-104, is &#9679;%. For purposes hereof, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the Commission in the United States and NI 62-104 in Canada. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section 13(d) of the Exchange Act and the applicable regulations of the Commission in the United States.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date to Effect Conversion: ________________________________</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of Series 1 Preferred Shares owned prior to Conversion: ________________________</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of Series 1 Preferred Shares to be Converted: ____________________________</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number Common Shares to be Issued: __________________________________</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Address for delivery of physical certificates: _______________________________</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Or </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for DWAC Delivery: ______________________________________________</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DWAC Instructions: ___________________________________________</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Account no: ________________________________________</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:57.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top"  style="width:52.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HOLDER</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:44.96%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:57.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">SCHEDULE B</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OPTION CONVERSION</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SERIES 1 PREFERRED SHARES)</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Xenon Pharmaceuticals Inc. (the &#8220;<font style="font-weight:bold;">Corporation</font>&#8221;) hereby irrevocably elects to cause the undersigned Holder to convert &#9679; Series 1 Preferred Shares of the Corporation (the &#8220;<font style="font-weight:bold;">Preferred Shares</font>&#8221;), into common shares of the Corporation (the &#8220;<font style="font-weight:bold;">Common Shares</font>&#8221;), as of the date written below. If securities are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in the schedule of rights, privileges, restrictions and conditions attaching to the Series 1 Preferred Shares (the &#8220;<font style="font-weight:bold;">Series 1 Preferred Share Rights</font>&#8221;). </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the date hereof, the number of Common Shares beneficially owned by the undersigned Holder (together with such Holder&#8217;s affiliates, and any other Person whose beneficial ownership of Common Shares would be aggregated with the Holder&#8217;s for purposes of Section 13(d) or Section 16 of the Exchange Act and the applicable regulations of the Securities and Exchange Commission (the &#8220;<font style="font-weight:bold;">Commission</font>&#8221;) in the United States and National Instrument 62-104 &#8211; <font style="font-style:italic;">Take-Over Bids and Issuer Bids </font>(&#8220;<font style="font-weight:bold;">NI 62-104</font>&#8221;) in Canada, including any &#8220;group&#8221; of which the Holder is a member (the foregoing, &#8220;<font style="font-weight:bold;">Attribution Parties</font>&#8221;)), including the number of Common Shares issuable upon conversion of the Series 1 Preferred Shares subject to this Notice of Conversion, but excluding the number of Common Shares which are issuable upon (A) conversion of the remaining, unconverted Series 1 Preferred Shares beneficially owned by such Holder or any of its Attribution Parties, and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) where such Common Shares are not deemed to be beneficially owned by the holder under the Exchange Act or NI 62-104, is &#9679;%. For purposes hereof, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the Commission in the United States and NI 62-104 in Canada. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section 13(d) of the Exchange Act and the applicable regulations of the Commission in the United States.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date to Effect Conversion: __________________________________</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of Series 1 Preferred Shares owned prior to Conversion: _______________________</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of Series 1 Preferred Shares to be Converted: ____________________________</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number Common Shares to be Issued: __________________________________</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manner of Issuance of Common Shares: ___________________________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top"  style="width:52.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XENON PHARMACEUTICALS INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:44.96%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:57.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To be completed by the Holder:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Address for delivery of physical certificates: __________________________________</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Or</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for DWAC Delivery: ____________________________________________</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DWAC Instructions:&nbsp;&nbsp;____________________________________________</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Account no: ______________________________________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top"  style="width:52.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HOLDER</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:44.96%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&#160;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:47.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="bottom"  style="width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:44.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:57.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;"><font style="text-decoration:underline;"><br /></font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><font style="text-decoration:underline;">Schedule B</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SHAREHOLDERS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:30.75pt;">
<td valign="top"  style="width:20.16%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shareholder Name</p></td>
<td valign="top"  style="width:14.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction of Organization</p></td>
<td valign="top"  style="width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Business Address</p></td>
<td valign="top"  style="width:17.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Physical Certificate Custody Address</p></td>
<td valign="top"  style="width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchanged Shares</p></td>
<td valign="top"  style="width:19.3%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred Shares</p></td>
</tr>
<tr style="height:75.75pt;">
<td valign="top"  style="width:20.16%; border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biotechnology Value Fund, L.P.</p></td>
<td valign="top"  style="width:14.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One Sansome Street 30th FL San Francisco CA 94949</p></td>
<td valign="top"  style="width:17.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jefferies LLC<br />Attn: SCC Clearance Area<br />101 Hudson Street, 11th Floor<br />Jersey City, NJ 07302</p></td>
<td valign="top"  style="width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,338,000</p></td>
<td valign="top"  style="width:19.3%; border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,338,000</p></td>
</tr>
<tr style="height:75.75pt;">
<td valign="top"  style="width:20.16%; border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biotechnology Value Fund II, L.P.</p></td>
<td valign="top"  style="width:14.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One Sansome Street 30th FL San Francisco CA 94949</p></td>
<td valign="top"  style="width:17.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jefferies LLC<br />Attn: SCC Clearance Area<br />101 Hudson Street, 11th Floor<br />Jersey City, NJ 07302</p></td>
<td valign="top"  style="width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861,000</p></td>
<td valign="top"  style="width:19.3%; border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861,000</p></td>
</tr>
<tr style="height:90.75pt;">
<td valign="top"  style="width:20.16%; border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biotechnology Value Trading Fund OS, L.P.</p></td>
<td valign="top"  style="width:14.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cayman Islands</p></td>
<td valign="top"  style="width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands</p></td>
<td valign="top"  style="width:17.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Depository Trust Company<br />570 Washington Boulevard &#8211; 5th Floor<br />Jersey City, NJ 07310<br />Attn: BNY Mellon Branch Deposit Department</p></td>
<td valign="top"  style="width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238,000</p></td>
<td valign="top"  style="width:19.3%; border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238,000</p></td>
</tr>
<tr style="height:75.75pt;">
<td valign="top"  style="width:20.16%; border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment 10, L.L.C.</p></td>
<td valign="top"  style="width:14.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Illinois</p></td>
<td valign="top"  style="width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">900 N. Michigan Ave, Suite 1100<br />Chicago, IL 60611</p></td>
<td valign="top"  style="width:17.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jefferies LLC<br />Attn: SCC Clearance Area<br />101 Hudson Street, 11th Floor<br />Jersey City, NJ 07302</p></td>
<td valign="top"  style="width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152,000</p></td>
<td valign="top"  style="width:19.3%; border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152,000</p></td>
</tr>
<tr style="height:68.35pt;">
<td valign="top"  style="width:20.16%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MSI BVF SPV L.L.C.</p></td>
<td valign="top"  style="width:14.52%; border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="width:15.8%; border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200 Park Ave, 56th Floor New York, NY 10166</p></td>
<td valign="top"  style="width:17.38%; border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNP Paribas Prime Brokerage, Inc.<br />787 7th&nbsp;&nbsp;Ave, 8th floor<br />New York , NY 10019<br />Attn: Jose A. Nevarez&nbsp;&nbsp; </p></td>
<td valign="top"  style="width:12.84%; border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279,000</p></td>
<td valign="top"  style="width:19.3%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279,000</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>xene-ex991_9.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
xene-ex991_9.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018032803583929231798.jpg" title="" alt="" style="width:147px;height:39px;"></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#595959;font-size:20pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">NEWS RELEASE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BURNABY, British Columbia,&#160;March 28, 2018 --&#160;Xenon Pharmaceuticals Inc.&#160;(Nasdaq:XENE), a clinical stage biopharmaceutical company, today reported the closing of the previously announced transaction with Teva Pharmaceuticals International GmbH, along with Teva Canada Limited (collectively, &#8220;Teva&#8221;), to terminate by mutual agreement the collaborative development and license agreement dated December 7, 2012, as amended. In connection with the closing of such transaction, Xenon has cancelled 1,000,000 common shares of Xenon that were owned by Teva. Teva will also return, license or assign to Xenon certain intellectual property including certain patent rights and will transfer regulatory filings related to TV-45070 to Xenon. The termination agreement requires Xenon to pay a low single-digit percentage royalty to Teva based on net sales of approved products, if any, resulting from any continued development and commercialization of TV-45070 by Xenon during the period that assigned or licensed patents cover such products. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 23, 2018, the Ontario Securities Commission issued an order granting Xenon exemptive relief from the requirements related to issuer bids under applicable Canadian securities laws in connection with the transfer and assignment to Xenon by Teva Canada Limited of the common shares that have been cancelled by Xenon. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Simon Pimstone, Xenon&#8217;s Chief Executive Officer stated, &#8220;We are pleased to close the previously announced Teva transaction, which is accretive to all of Xenon&#8217;s shareholders. We also announced today an agreement with Biotechnology Value Fund, or BVF, Xenon&#8217;s largest shareholder, to exchange a number of common shares for Series 1 preferred shares, allowing BVF to maintain a common share position that stays below a threshold of less than 20% of all Xenon common shares outstanding following the Teva transaction. BVF is our largest shareholder and has been consistently supportive of our growth and strategic direction. Following the conversion to preferred shares, BVF now has greater flexibility with respect to their ownership position, including the opportunity to increase their common share position in Xenon.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 23, 2018, Xenon and <font style="color:#000000;">certain funds affiliated with BVF Partners L.P.</font> (collectively, &#8220;BVF&#8221;) entered into an agreement to allow for a one-for-one exchange of common shares of Xenon for Series 1 preferred shares of Xenon. BVF, an existing shareholder of Xenon, held a number of common shares of Xenon, representing approximately 19.9% of Xenon&#8217;s outstanding common shares prior to the closing of the exchange and the Teva transaction. Following entry into the exchange agreement, Xenon filed articles of amendment with the Director of Industry Canada to create an unlimited number of Series 1 preferred shares of Xenon. Pursuant to the exchange agreement, BVF has exchanged an aggregate of 2,868,000 common shares of Xenon for 2,868,000 Series 1 preferred shares of Xenon. <font style="color:#000000;">A material change report in respect of the BVF transaction was not filed in Canada at least 21 days in advance of the closing of such transaction in order to permit Xenon to close the BVF transaction in a timeframe consistent with usual market practice for transactions of this nature.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The BVF share exchange closed on March 27, 2018. Subsequently, also on March 27, 2018, Xenon cancelled the 1,000,000 common shares transferred by Teva. Following the closing of these transactions, there were 14,171,301 common shares and 2,868,000 Series 1 preferred shares of Xenon outstanding.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">About Xenon Pharmaceuticals Inc.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing &#8211; both independently and with our collaborators &#8211; a novel product pipeline of central nervous system, or CNS, therapies to address areas of high unmet medical need, such as epilepsy, migraine, and pain. For more information, please visit <font style="text-decoration:underline;">www.xenon-pharma.com</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;"><br /></font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="text-decoration:underline;">Safe Harbor Statement</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding our relationship with our current shareholders and our expectations regarding our current shareholders&#8217; ownership position in our company. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: our current shareholders may not increase their ownership position in our company; clinical trials may not demonstrate safety and efficacy of any of our or our collaborators' product candidates; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; our efforts to expand our current pipeline may not be successful; any of our or our collaborators' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission and the securities commissions in British Columbia, Alberta and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Xenon&#8221; and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investor/Media Contact<font style="font-weight:normal;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jodi Regts<br />VP, Corporate Affairs &amp; Investor Relations<br />Xenon Pharmaceuticals Inc.<br />Phone: 604.484.3353<br />Email: <font style="text-decoration:underline;">investors@xenon-pharma.com</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g2018032803583996429431.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018032803583996429431.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )  X,# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WR1UC0NQ
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MX/&*S;K53'"TR>7#;J.;BX;:GX#J:YDRVFF>'M/N9Q<+;V8;R;9LJT\A]1W
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M2NGI$=K>](P=.$CW^L0@G>D) \L ,"  -N>@X[ULV.IW.FW,J;A+'O;*$X0
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M<S?*R,:_I33>2+^'S/[N:Y;Q#I^@:CJ#74NJ)!F/:RQ=VS]XFNL^PR9&?LQ
M/(\D4AL9,G ML>AA%)IO<<6HNZ.:?Q19_P#"*.BW6;M4^SCKEC]W=].]5-*L
M-#TC4()!J$,\ZKL=)7&,G^(=JZ[[!/CI9D^\%-.FS$8V6/\ WX%+E?4I225D
M))XBTB%]C:C;@@X.&SBA_$FCI'O;48-OJ#FGC3I%'"V8/M *9_9MP/NO:*?4
M6XJKR(M$@;Q!H=_:2*;V%X64JP(/\L5R%K_8GA^>&^L+VXGFC?;*NTD.C'!P
M,=J[G[!==[B'/M;K2BRO,?\ 'VF?7R%J6FRXR2T.0UK4-%U[5XHKFZ9;.UA+
MYVL [D].GI6MI.K>'-*TX16EVJQ#D[D;<2?7CFM8Z??$Y-_'CT^S+0-/O^]_
M&?\ MV6BSO<')6MT*R>+M%>38+L@^IC8#\\5)+XGT>(J&O%YX!56/]*L?8KW
M'-Y&?^V I#97N>+N(?\ ;!:KWB?=,+Q'-H6K6<,=Q=-E'#JT:$MCTZ=ZRM%U
MG3]%NKFVBDNCI\D8EB\R(GRY,<KTKLQ9WP_Y?(_^_ IQM+XC_C]7_ORM3RN]
MRE-)6//+:WTBZ@^UZC<21WTTIE+%&^7!R%(QT-=HOBG2((XDFO(ED90=JJ2/
MY5=^Q7W_ #_+_P!^%IO]GW74W<9/<_9UYH46M@E-2W(6\3:.KE#?1[@<=#_A
M4">*=$GG, O"C*?O%64'\<<U;6POAG_3(@/06ZT_[!=D?\?41],VZ\4_>)]T
MXG4H_#5[J%S<":<23'(DBR%1@.,#'<BIK[Q%9ZKHMC8RM)')+(J71,9^5!U.
M?>NP^PW8_P"7F$_]L%H-E>=KB#WS *7*R^=:>1S6E7'AW2M0:2RN(X^"DOF;
MB"!W!QUK:LO%6D7\IBAN_P!X#@*ZE=W..,]:M&QN^/WML?K *RM5AG:VF@D6
M!I$E@:-XXPI&7YH2<1.TMS<NXYPGF6BQ^>00&D)P/RKE/&<&JW#69M)/+\M3
MYKB78,Y'Z5UNHW\6GV;W,SJJ+@99L#)]Z\[GG+S.[2VS2.^W:(GG90>5'/'N
M?I14:M8*2=[E&VM=52=%:]M2/NKYN'P_9<CG(_2I=1O(;C7(6O$<Z5O7S?*!
M&YL=2#VX_*NCTRQ-OHKWEQ#+*TA(6,(J[5S]\ =^]<E=WDEQ<J[M&OD/CRY#
M@LQ&%Z<G Y.:R:Y4;Q?,V=I<_P!HL^='GT]+5HE^Q&1247UZ<9KHM+2]CL(5
MU"2.2Y ^=XUPI-><Z'J$%G=?V5<S13:;=L1'AL^4P.-W/3)KTJRD+P[&SOC.
MQL^U:TW?4PJ*VA9HHHK4R,+7;P6D-S=L>+. N!ZN>!7F$$R_9-TDMPQ8EY&
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M "BBB@!,44M% "8HQ2T4 )2T44 )^%+110 4F*6B@!,>U&/:EHH 3%&*6DH
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M_P JOULMC![A1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCF@#2'B$PV5Y)>V_EW-K((FAC;=O9AE=OKG(JQ!K2R>&SK$L1B"P-*\9/*D
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M>D\7_?8JL-(TXC/V*'_OBG?V1IW_ #YP_P#?- %C[1#_ ,]H_P#OH4?:(/\
MGM'_ -]"H!I-@.EI$/\ @-']E6'_ #Z1?]\T 6U96&5((]0:6LO155+6=$&%
M6XD 'IS6I0 F*6BB@ HHHH 0L%&20![TSSHO^>L?_?0K.UF*.X:QAF0/')<@
M,IZ'Y33O^$?TDC_CQB_6@"_Y\7_/6/\ [Z%)Y\/_ #UC_P"^A5$^'=((P;"+
MCZT#P]I(Z6$7'L: +WGQ?\]8_P#OH4OG1_\ /1/^^A5'^P-*'2QB_(T-H>E@
M$FSBX&>] %[S8_\ GHG_ 'T*7S8_[Z_F*Q[6ST&]RUM#!)MQG&>,]*L+I.E-
M]VVB/T/_ ->@#0\R/^^OYBCS$_OK^=9LFFZ1$Z*UO$"[;%'/)]*5-+TF5=ZV
M\3 9&03VZ]Z -+>G]Y?SI/,3^^OYU1_L;3,?\>L>/J?\:4:)II&?LB?F?\:
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ML?\ WT*RK?3=#NTWPV\#KWQVJ7^PM('/V*&@#0\^+_GK'_WT*//B_P">J?\
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M 4444 97ATYTA?\ KK)_Z$:U:R/#?_('7_KK+_Z&:UZ "BBB@ HHHH ****
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M -#>M*LV/_D99Q_TZ1_^AO6E0 4444 %%%% %'6?^0+>?]<6_E5BU_X](?\
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ME0L70%>,\$@\8[5<U)(CK20K,+>-PGF28R8B5"L#BL'*Z-U&S+NG:1'J-_\
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M>_\ @,_^%:?XT4 9G]O6Q_Y87O\ X"O_ (4#7K4_\L+W_P !9/\ "M/CUHH
MR_[?M<X\B^_\!)/\*/[?M>/W%]_X!R?_ !-:E''K0!F?V_:?\\KW_P  Y?\
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M $\?^ [_ .%:5% '.ZQJ<-YITD$$=PTK.FT>0XS\P]JZ*DI: "BBB@ HHHH
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MU#J3)&Z>4$,;,N001U%=:#7/6/A<P7%A+=:A+=+8+MMHBBJJG&,G'4XKHA0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %<YXC_U6H$]].<?K71]JYKQ*=L=^?33G_\
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MQGV'2KZ>([XZC_9)MX1?$IM<,3'AD+<]_P"$U.W@C1G,N^.=ED,AV&4X7?\
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MWUG=OI[6B->(S$F-7=2H4$8 &<G<![5'-X@U'4E@>VMQ;0+<6RS"1B) 7()
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M(TO_ (^#_P!>L/\ (UK]JVCL8RW%HHHJB0HHHH **** "BBB@ HHHH ****
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M]%_Y EC_ -<%_E5ZJ&BC&B6/_7!/Y5?H **** "BBB@ HHHH **** "BBB@
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M?WU_.CS8_P"^OYB@!]%,\R/^^OYBCS4_OK^8H ?13/-C_P">B_\ ?0H\V/\
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MQL9OZ5,]BHJ[.<\7>(KB/2H--CB*?:;=6DEW=NXK*T*U_MH110KAHB X"*H
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M(PP5/0BJ7]AZ;_SY0_\ ?-:%% &=_8.E_P#/E#_WS2?V#I?>PMS_ , %:5%
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MK7HH Q_^$8TG_GW;_OXW^-'_  C&DG_EW;_OZW^-;%% &,?"VDGCR'_[_/\
MXTG_  BNDC_EA)_W_?\ QK:HH Q?^$5TG_GC+_W_ '_QH_X172O^>4W_ '_?
M_&MJB@#%_P"$5TG_ )Y3?^!$G^-!\*:0>L$W_@1)_P#%5M44 8O_  BND_\
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MGH:WC\)A-^\0:* )(<?\^,-;E8ND?ZZ(^MC%6T*J)G+<****H04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !I,>(?[VE_]\R?XU>%_:,!B=#E/,&&_A]?I4-MK&FWK[+:]AE;=MPC@\^E
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M'A8J/O \,#WJG)H.I^5-<_OC<B]2=8%D C;:!SCZT7WB&^^R?VA;7""UG9Q
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M,$?6IJY72]4OC>:5]HNEN8]3B>7RU0+Y. #P1U'..:ZF@#.T'_D#0?\  O\
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M-+3$%%%% !1110 4444 4-:_Y UW_P!<S5T?='TJEK?_ "!KO_KF:N_P<>E
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M% &?K?\ R!;O_KF:O#H*I:U_R!KS_KD:NXXQ0!YI*\0L;AK1G_M+S;LS\O\
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M[F@#F(;NVN8;NXO1=)>/!NM(V#AU?S). ![X_"MS7(M0>[@@B,PDGM5F)0G
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M 5M+TB_U1YI9PUO$SS+)(LS;Y#G"C'8 \\>E686U ^#+B^N)93=SL#*8\Y1
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M% $/V2V_Y]XO^^!1]EM_^>$7_? J:B@"-8(D.4B13ZJH%/Q2T4 )@48%+10
MF!2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/K',\2XZP3@_\
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M)(E:7Y<OM9<A.>0<$\T :EWX=TUC8VS74D,L4/E6^'&]L%6)YZG(!J!(M/\
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M3;R"RO1Y*6H8M;IO!1B3M7.& 'K7>:0\CZ=&94F5^0?.B$;?]\C@4 9T?A:
MWAO+JXENKASAWDQ\R[2H7 XQR3^-5U\&11VD%FFH71LXMN87(;.&W @D9!KJ
M** $H-&:6@#.T/\ Y UO]#_,UHUG:%SHMN?9O_0C6C0 4444 %%%% !1110
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MG@4W:>U Q#[TH QFD/(^E'(Q0 ,..>U-R,4K-D4F-PH %/.:?NSFFKR<"G4
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MT]EX<L]9M[-X$2[NE=T0 X< 8.>W2HK34/#5EH[2VN/LEPCLP4%BX4A"/P)
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MM.LOPZ<Z!:'_ &3_ .A&M2@ K"\0:?=WPA$5M:7=N"WFV]R/O9'!#=L5NTE
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MAE5.2&/4$\_6O49=)AU7P[':72_?0-N[HQYR/SKS3PIYIU*\G9#&8K J 7W
MEVQD?W?I7<>+KK6=-TV&7365;=5Q*0N67T/TIT_A;"IK))'G6LZ3<:+?-:7
MZ<HXZ.OK6:6S4]U>7-Y)YMQ/),Y_B=LG%5\9XKFE:^AU)-;B;J*7'%&*D;%%
M+R/QIN:=GB@!!FD.0:=UXII]:!B#DT[M36XI>PI!<3::>.F#WI <T#I0)ATI
MN.>*>/6G"F-#-O%&[Y:7/%(W44 *I);T J2(;YD4$#<<9/2F@=\T=&IH+'KO
MA?P];:3:+.'2>XD&6E7D#V!KHZ\H\+6.N7,ZM87$MM;@Y:1LE#]!WKU6,$(H
M8Y8#D^M=M.5UL>?534M7<S?$IQX<OO\ KG_45IGH:RO$XSX;OA_TS_J*UNQK
M0S.;_P"$@<6\E^=,;^S\.%F4C<2IP,CT8\"J]WXL;2YHH-4TXQ/*Z$"-@X"-
MG+'Z8YJU_P (K"R/ ]Y<FR.\I;;L*A;KSWP>0.U*/"T4EQ%<7UU->31$!3(
M!M (VX'KN.: *;^*6::6*UTQ)8X8I)ICO ^1'*Y'KTS3SXFNY?L[V6GQ26\U
MU]FC=Y=ISC.<8Z8%)#X'MK90EM?7<49C:%U# EXV<L1GMUQ]*TX?#MK!'#'&
M7"0W?VI!GHV,8^G-,#-7Q+/<FY-EIJR"V#-<EGV]"1A?4_*3S4<7C.RNV=4L
MY'87*PJA4$NI4L''J.,?6K?_  BD43RFVO;F 3AEG"$?O%))_ C)&?2AO!NG
M%[:16G1K:9I8RCX(W#!!]0.H]Z0$VCZZNJ:=-=R0QI'$-WR.'P,9((ZAA6?<
M>*WM((9[BP1#<HLEJQD'*,P'S'L?F!K4TW0([%;HR3R7,ERHCD>0 $J 0,XZ
MG!.3WJHOA& B$7%U<7"V^U8%D(_=HK X]^@&?:@":ZUMK;14O7AA<R2B/]W)
ME%R<;BV.E1KXD003O+:;3#:?:B$=6!&XC@CZ9K3O],^UVJQ0S-:LKA@8U&#[
M$="/:L=/!EO%;K#'=SH&C:*<@#]ZK-N(_P!GDGI0!5MO&T=S]H;[$6\OS@$1
MPSGR^N1Z&IW\3X@MF:UMBUQ*T:N9P8SA=V<_IC%/A\%VT+,5O;D*)))8@I"F
M-GZG/4T+X-A67[0M[*+HS&9I/+4@DIL^[TZ4 /E\0R11S3+8*UK:;1<2*X^4
MD G8.^ :9=>*8+?1H=1-MN28R +D?P9ZG\*?>>%/M4<B+J5U"LS*TZ(!ME*@
M#IV! Y%))X/@FB,#W<_V<"3RHAC$1?K@]_:@"O\ \)=%;W6GPSVT0CNV=?-M
MY Z1!0.6].3BK%IK]W>7MK##IL8CN(3,',H!50VT\8]34H\*0231/=W#W'EQ
MR1!2BJ-K@ YQWX'-6--\/V^EFS\F25C:6S6Z%VR2I(.3[\4 57UR./5[BS%D
M@%JK.3N ?A<[@OH>F15)?&#-9PSBUM2MQ(J*/M(P-REOF]#Q6G<^&TNM1:ZE
MNYF3+,L1Q\C,NTX/7&#TZ9J&V\*11);17%Q]IAMG#1QM @'"E?FQ][@]Z ,Y
MO&\(AA<68WR,$5FD4(?G*Y#>G'!JPOBAFN+.!K.!FN!ORLXVL-VWY#T8CN*>
M_@FUVQ"&ZFC\E@800&" ,6"X/!')J2;PF;A(DGU"5XT(WH(U4-@Y&/[I]QVH
M WQ#$1_JT/\ P$4_RD)!*+D=#CI4=K#)#%MDF:5LD[F&#R:GH C\B+G]VG/7
MY1S2+!&K[U10VW;D#MZ5(3BEH 88D(P44CTQ33;PG&8DX.0-HX-2T4 ,,:D<
MJ#GKD=:/+7.=HSZXI]% $0AC5=JQJ 3D@*!0T,<@(=%8'J".M2T4 ,\I,8VK
MC&,8[>E(L$2R%Q&@<]6"C)J2B@!AB0C&U=OIBD:"-OO1HW?E<U)10 BJ%&%
M ]!0W0_2EI&^Z?I0!E>&N?#MG_NG_P!"-:U8_A<Y\-V1_P!@_P#H1K8H ***
M* "BBB@ HHHH ***2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L;6/^/[31_MR_\
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M(MM.C:T:W&]9EWS;&R>>PQSSS5>X\/W5S9PV>^PC6W@EC\WSANG+MQGVQZT
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M_P"@&E+8:W/)?*73O#-KK%@;BSNO/,;R%SB4Y).!T(X'-;VD>,DU2/[)K*)
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M2R&?]E<_SK7BT^Q0EDLK=&/4B,4CZ5ISD2&QMF8<@F)?\*NS(NC';6K?AO\
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MNLZ)"Y@M65$_TA"@_=L!Z5MQ6]FJ*L=O$J@84",8Q5*[5T2[)V9SW_"26))
M\30D].+:G'7K49!\3Q*1V:V _G6Y):6ENTEPZ0I'MRV5  QWKS_7_%-G'J&[
M3?(NX7&91*F5##I@T2;BM1Q2D]#HSKMMR/\ A*+<>O\ HZ\4+KUL1\OBF!OI
M;*:JZ#I$4^BS-J-O$9]3)=@$ V@] /;O7.P^))=+U%+*YL+(16\GES2)%\S!
M>,^F<5/,U:Y2@FVD=8VNVZ8W^*8$STWVH&:?_;,0&[_A)8,=,_916U#_ &=J
M-O'/''!/$P!5M@-*%L3/-'Y46^-07!0<#M5V9EH8PUF ]/$UE^,:Y_G2_P!L
M1G[OB6Q/_;-?\:O?V3I",]VEE:1NP/[[RQGGO7GUYJUE?27&F6>EP-=7$GV?
M[1&@PXS]\#UZU,I-;EJ*EL=J-73_ *&&Q/\ P%?\:0ZPJD9\0:?S_LC_ !K&
MUO0M-TC3;>^ATZ*3[(-DZ8V^8K#!)]P>:B\)7VCW]S<0#3;>.=5!A$F&,@Q@
MTN9WLPY5:YT']L*PRNO:=[9Q_C2?VNP;_D/::1CD<?XU:AT?1(9F,>FVJ2E<
MOB,<?6IQH^E,C;=.MBL@Y_=CFKLR;Q,\:PS'"ZWIAYQ]X?XT]=2G//\ ;&EG
MZ./\:S?$T.DZ9IF4M[(21MO6V:,8<_SKFM"@MM<UFW8:9%'96BEI!MR&)Z+^
M%0Y-.Q:@FKG>?VA-C/\ :FF_]]C_ !I/[1FX/]IZ81_UT_\ KUPVKV^G:!?R
MQ/I$=Q%<'[1 Y.W;G(*GV_QKJ="CT?5])@:+3;,H5Q-&$&484U)MV$XI*Y?.
MIS#KJ6D_C+_]>C^TKC'&H:3^,O\ ]>K*:#HR1[$TRU"],>4*@_X1?00^[^R+
M3)[^6*JS)NAG]J3_ /02TC'?][_]>E35)Y"=FH:2PSVE_P#KUS_BB^\/:7<1
M1+I=K<7!'S;  4 Z9X]:/#^B:=K>GW>H7>G11->L5B0)_JU P"/QYS4W=[%<
MJM=G1-J,X/\ Q_Z6/K+_ /7I/[2N,<7^D\?]-?\ Z]<-;ZMIMK?PV=YH=NLL
M,@AFE/(PO&['KBN^ET/1+Q4EDTZUE!'RMY8Y%$6Y;!*/+N0C5+CO?Z3^$O\
M]>ICJ1\C OM/\[/'[WY?YYJ7^PM(9-O]FVVW&,>6*A&BZ39P,S6=K&%!^?RP
M,56J)T$.HW'\-YIA_P"VO_UZ!J%T1_Q\::3_ -=J\]NM2TYIYK&STNW>=V:"
M.=!@,#P&QZUN:YX?L-,TRUOH["*<V("W,?02J>"?J#S4J;9;@EN=,=1NP/\
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M-<M]&TK5FMI[>6-6 DC:"1MNW^Z5S2DVEJ5%)['8IJ/B$YW:/;#Z70_PI_\
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MLCNT V.'595( (Z'TJ[(L5Q \>59'4J<'L:\@LM:UJR1DBOF(CQ^ZE^;//0
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M]WW*'8YX*$\$<5SJ!%# "3S&3S0 V3,AR0P/9E_7%/$-RTT-K;3MYMX<)Y+
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*6/:BG45T'.?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g2018032803583929231798.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018032803583929231798.jpg
M_]C_X  02D9)1@ ! 0$       #_[@ .061O8F4 9      !_]L 0P ! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @("
M @(" @(# P,# P,# P,#_]L 0P$! 0$! 0$" 0$" @(! @(# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\  $0@
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M=+NCW1M\?,N1AKF2A64P;HYB>PX X X X X X X X X X X X X X X X X
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ME%%9*F?6E5#U  PPH^?Q3$/ARP)9S5J?D+9+J.W[Q?UJ;"92LF?=.MGF3_\
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M-HQU-P%>M>6HZ],Y6<J\G$02B<2T1.RMK9ZZ79Q:A7B D!-X5,??3$H!ZR^
MV\*LL-X3EQ!Q.=;%;G\>75U3M.JT\R6R)Q)K_/1K.9@\98=FHB10(ZCY6)IE
M*D8U^V4_EN&;YG&K-72!_'P.0QBC\AYK=UUHVY.JL/'LIK6C3^",A_0W"G_9
M_%O_ (_J?_*..^_B_F7T,'[*_)$)?83(X(QIOCUMM8=SB>@*U7+$A-9#3B@J
M=7/7(I])T<863NAV1&/VJ/<$26,V5?&(GZ 4.40+ZC<VL/>\-YEZ:?4XW/>#
M'SN.J]E8M+V4;1)8!070=((N6RR3ALX237;N$%"+(+H+$!1)9%5,3)JI*IF
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M02%\,[3RMK^'U^IT?;:Y*\.BR2GK">Z4N/I!WKSQ-X< < < < < < < < <
M< < < < < < < < < < ^/Y?]'_#@'D/'@/'CQ\O'X?W>. >> :WMG](?O\
M"?KK^F_ZH_+^G/U9^F/O_P#-'T_9/O'^T?YWGQ['^=_;S)=T:3!YW]+N7?V]
IW28G^1LCF)Z#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g2018032803583998729432.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018032803583998729432.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )  W$# 2(  A$! Q$!_\0
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M\Y_Q_A^E)NU[;G[/IN[/_/9__B: -7J,BCOBLI6UXG+V^F_A/(?_ &2@MK^
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M'^]EW(<@J2<':W)'\5 'H2:C920O,EY;M"G#R"5=J_4YXH34;&21(TO+=G<
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M!0RL=@2-6 8CALJ<'''!JEIOA/6(]7%W=)&81J<=T!-=M/)L6$IDL1R<X.*
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M5:T\YTZU/_3)>WL* +'?IS0,<8]*.:!G_P"M0 M%%% !2>F?7CB@]:.WI]*
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MN),81&\QB JEW!R,>AZ]*M:=KUYJ?B73 US!';RQW1-HF1("A51O&3DCGL*
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M?-U%+<*X0(B[6P(\LW/'/'/TH [)9==_BL]/_"Y?_P"(I?-UO(S9V!^ER_\
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M]C7I(W#R6XQ[5+IX_P");:C''DIP1TX% %@>QH'7KSCFCWH'88P/:@!:***
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MT$G@9YK0[]._:@>WUYH /PHS[4<<=>M'\R.F: (H;:&%Y7A4!YFWR-U+'_\
M54OKP>GK0??I[4'OQ^M !QGKWQUHR<9Z_2CO1[CKCO0 =_Q[]Z/3KUH/?W//
M-''OUH 3T]<<9[4O-'8#IQTSS1C_ #F@ SSG.,=<^E'.?YG'6C)P>F<=.M'<
MX';UH /J:3CU7D@TO-'- %#6\_V%?@$JWD/@_A4VG?\ (,M,C),*9_(5%K7_
M " [[&?]0_\ (U-88&G6H&<"),?D* +'<?CUI!CC&.G4"E_#OW-'7'7D?2@!
M:*** $/44<\=?\*#U'^-)]/?M0 OTP>.M9-S_P C7IY')%I/V_VH^]:W?Z5D
MW  \5Z=_UZ3XY_VHZ -;J2,#W^E'_ ?>@9]>PZBCGU'Y4 )VQCC'W:7KP>>:
M.^*#Z'U]* $R.N0/_K4O_ N]&?YT?A0 <'C(((I!CJ0/7-+GWZ\XQ0,X'T]*
M #Z')YHZ<# QBCJ.AHS_ )Q0 >V<&CC/09SGFCV/YBCKV- "<<=.II>>.OK1
MGI]?2@=N#^=  ,\#IBCG'4FDXQC&.,<4OY^M !T![ #\!1CC&!CI^%'3VP.I
M-''7GU[T !S_ /JH_(9/YT>W/IUH&?3'KF@ []QFDXXX'7IZ4N*,].>OM0 G
M4>N1^!I3GGGMT%)VY&>.>/Z4O/(Z\=J #_@73FCVR3TH_"CKV- "8' P,=!]
M*7CZ=Z.>WZT<_6@ [^N#^5)GH3U YSVI?P/%'L/3O0 AZ'('3FE]>W/YT=\C
MOQTHX]Z  \C!P,^M)QSTZ\\TOTSS@T9/MUH /J/P]*/3(&>W-'TSFCOU'6@
MY]/SHR/[U [>W'6C\* $R,]?7O1QC!"\#UZ"ER<>G'I1G_.* $XYZ=12_P#
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M7/<&@ X_ Y&,5DW#9\6:<N#_ ,>DY_\ 'HZUN?K61<X/BW3N.1:7!!]?FBH
MU^HY''I1QSD=N>*!ZC\_6CGU'Y4 5;AK\2XMX+=X_624J<_0*:KF76P3ML[
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MV_\ BJ0V^O'K?V&,\_Z*W3_ONM7OU%)V[D8].: ,K[/K^/\ D(6&[U^R-_\
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M ^#_ +YI/^$>TC&/[.M\>FW_ #ZT :.4(R".3V/>EX]>A]:S1X>T@=-.M_\
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M]>?RI: $XXHY[_E2TG<9'.* #/&3Z=*6DZ#D]NM+0 A^N*.,^O/Y4M)^!ZT
M+112<<4 '<9/..E+2#CC&/I2T (>N3C@=:.,^]'?..U'M0 <<\=_2EI.:6@
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M.VEQ]?\ GZ'_ ,32?:M4V@G2DW<9'VH<?I0!I4AQWK-%YJQ7)TF,'/3[6/\
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M/>EI/7KUJ"ZEN(D4VUL)V)Y7S F/SH GXXHYK-^VZK_T"%_\"E_PH%YJA/\
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M6.<6-OUX_??_ %J -.D^G'/I6<)]7YS96P_[;'G]*3S]8R/]"ML8Y_?GK^5
M&E_*CGN*SA-JY_Y=+89(X\T\#\J3S=9./]%M!D]Y#Q^E &ESCMTZT5FF;6,?
M\>5M[_OS_A09M8/_ "Y6H&>\Q/\ 2@#3I#CO6;YVM<?Z):>^)3S^E)YNMEL_
M9K,+GH9&SC\J -/CCZ]J6LG?KV"!!IZX/&78Y_2DW>(CG$>FC'3+/S0!K<9]
MZ#TY'&.:R"WB(XQ'IHXYRS]:>/[?S\QTT>F!)0!J'&>?;BEK+_XGW.#IOMP]
M&-=YRVG>WRO_ (T :E)SZ5F,-=Q\ITWKP"'I/^)_GKIN/I)0!JTG?K661X@P
M,-IF>^5D_P : -?QRVFY]ED_QH U.?6EK("^(1QOTS SC"O^'>C9XA)YFTT#
MV1_\: -8XYR.W/%'-92IX@S\TVG$8_YYO_C3PNM_\]-/]_D?G]: -+//7O2U
MDK'K^[YI]/QCM&_^--:'Q"3Q>:>H_P"N+'^M &Q2<_7WK)6#7QC=>6)]?W+#
M^M)]FU__ )_[,>_V<Y_G0!L4G<XZXZ9K':UU\MQJ5JJ^GV?/]:/L6O%?^0Q
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MP:![&@9_^M0 M%%% !2?3GGUI:3]* %K*F/_ !5-H,?\NDO_ *$E:M94Q/\
MPE5F,_+]CE.,_P"TE &IWZ4M(.N1CD=:6@!/\]*,BCOWHYH 6BD&.U+0 44G
M&?>@=!QCVH 7M1WH[<4A]QQ0!GZ]?G2]!O;T9S#$2,=CTS6'<>(+RPO)8AY4
MEM;7%O:X(.^0R(IW9[8)KJ+B".ZMI;>9=T4J%''J",&F064$$$<2QJPC"@%@
M"?E& 2?4#O0!R9\:336]F;5;5I;B. G+Y$;23"/D#G &?KBJ.I^+=2ATN82/
M!&SQW4:31Y79)#C#DD\ D\BN[2RMHV+);0(Q/)6,9.#D?KS0]G:RKA[>%ASP
M4!'/7\Z ./?QC=07"V;-;3L9"/M</,>!&'QC(&[MUK4T'7+_ %G4)0\,$-K'
M;Q.0"2Y=P3P>F!BMK^S[(P>0;2 PYW;#&,9]<5,D4<9)2-5) !VC&<=* .*U
M+Q=<'2YY;=[=!*+E8^27A\L'EESW(Q[9%:>H:K<Z+HVF^6$D+QDRN[Y;A-Q(
M!.6R>O/ K=-A9F260VL.^48D;8,L/>G3VEM=1K'/!'*B]%=00* .2A\47*7<
MES)-;M827$4*\-\NZ'?GZ9'IT-00>-[R>Y%O!%;S23+;O$2"J@2N5Z9)( &>
MV:[0VMN5VF"/&X-C:.HX!J*+3+" DPV4"$D$E8P.1R* .<7Q;=/<SQQVJ,L0
MG0/)B-2\0/<MT)'IP"*6#Q'-=P6LZL1+'J26<T6PK]]0<$>HW @YQ72?8+,S
MR3FUA,L@VNY098>A]:A.CV0>U,<*Q);2&1(XP I;&,D=R* +QQC!]*,4$X[4
M''.1VYXZT +1110 GZ8_6EI._3H:6@ I.:..*/QH .W/7'4"EI.<8]NM+0 A
M^F:/SY/K0?KBCCMZ\XH 6D]*6B@!.:6D&...G>EH 3OG':CFCN>W'6CGUH .
M:6DXYY[^M+0 GI1S2TG/K0 M(>/I2TASV_*@!>^**.]% "9%+2?A1Z9]>.*
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ML%(!<*(Y%DW+N"XX/!R0,'UK3N-!M+N^O;F<R-]LM/LDL>[C9SG'H?FK)O\
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M&&1]=U9-]X @OKBX=M1F6.:>*<KY2EPT>W #GG;\GW?>@"Z?&$'VOR(].O9
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MJ 'T4SSHO^>B?]]"CS8L_P"L7C_:H <,<<YI:9YL?7S$QC/WJ/.B_P">B?\
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MUCQ-)_X#R>W^S[T :E)SZ5GG7=/ ),LF <?ZA^OY4G]NZ><XFDR!_P \'_\
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MBX_]FIJVFKC.[583]+3'_LU:0Z YZ^G- Q@<#KV]: ,XVFJ;\_VI%[#[*/\
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MYHS[]_2CVZ]^:._X]N] !GW%5IM.LKJXCN)K6&65,;'9 2.XJS],]^M'?I0
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M/[.-O:QN(D 7=AV/[O!!SQSF@#T[<IY##GT-(LL;[MDBMM^]@YQ7"2:'K?\
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MHH *3Z<\^M+2?I0 M8R_\CK+U_Y!R8]/]8U;-8Z9_P"$SFZ8_L],<<C]X_\
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M4 '3J>*6D[^_I2T %%%)QQ@=_P J (;NRM;^#R+N".>+<&V2+D9'3BI@,
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M]0"<=*4]?7IUH CAMX;?S##$J>8Y=]H^\QZD^]29_P ^M'ZX/>@8'3ITQB@
MR./0]Z,BCT.3S[4=>YY'I0 9'KUHR,<<\9XHR>P_.@YP3TQ[T '/I1D>M&/0
M8XP"*,@CIU]J #/MSZ4?A1^)Z^E)Z<=^.* %_"C/X'TH'/H>:/KW[4 &>,@9
MX[4?A0>F3@<=?2C'L.M !^%'X48/J:/7C/- !D49'J*.?_K4<T 'X49..AZ4
M<9XZ9[>M'0 D 8'Y4 ,:*)ITF:-3(@*JY'(!Z@?D*?SZC\J!QC@#CFCCN.]
M!GT(]J.:,^GY487ICVZ4 'L31^/YT<$8 Z]B*/Q/7TH .<CZ4#L/;H>M&/89
MQ1[=,=,4 )[<].F>E+GUXI.V,=N@I>_;ZT '/J/RH[]1UHX].F3THXZ#CGTH
M ,^X]*.:/Q/7TI/E]/7M0 O?.*3M@\\=#U-+CGU_I2#! '&".GM0 I/7D<4<
MT<]^/I1QZ=_2@ _'OV%&<X^O:C@=..@X%'/U^M !SZC\J#QS['GM1WYYYX]J
M3CC@>V: %[]11S1T/4_E1A>F/T]* #/X=.M&??OZ4=N<CCMVHYY]Z #OU[]Z
M.:/7COW-&%]/;I0 <\?7M1VP...AYHX["C' !';&.U !S1VZ].O%'![=1Z4<
MG/TH .Y]?I1SZC\J."3WHP/04 '?UY[=J!^'4]*/\?2CT^OI0 9XSN'3)HYH
M].OUHQGJ!TH .>F1[4=^OZ4=B0.W7%&.?04 '/J/RH]>W/>D^7T].U+^0YH
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M+<F242ME!\SK]UCQR1@59_ T?3CGTH S[C0])O!BYTVUES(9</$I^<@ M]2
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M^A]ZSAKNE9 %]'U]31_;NEE=WVZ+@=><4 :(R1U[=>]&.>@Y'-9W]O:42?\
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M<$4D:V>Y7"+^\D9MJHVY5&3P 1G%6+OP[I5[+/+<6@>266.=VR<ET&$/U H
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M,_6C _N^M !WHQQ@J,8H]L\^U'_ ?>@!"%Y^7/X487NOZ4I&%(XQ].U'?N*
M$PN,;?THP/[H_$4O/J/RHX/0@\=* $P,_='H>*, _P (_+_/O2]QGUXS2<=\
M=#UH 7"^G?TI-J_W1Z=*7GU'Y4'WQB@!"!CY@/4T;4/)4'ZBC\1GIT[TO?IW
MH 0JG=0>?2C8F.47&>.*7'H,=J3ISW_#F@!-B?W!_P!\T;$XRB_E3L=CR*!C
ML1GJ<=Z &[(P/N#U^[1Y:#.(U]> .:=S@=>GM28]>PZF@ \N/.=B_E2>7&!]
MQ?\ OFG>^WWHQV QVR* &^7'VC7CC[O2CRH\8\M,?[HIW?KW[CV[48']WUH
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M=12D\GD#CUH ,_YQ1UX_F*.?K0>G.,'@T '?CUYHY]1^5)]<?3-'!ZMD'^M
M"]^_6@=L=,=Z..W<^E(,'WXYSUH .W0].F:7IGKZTG;N>/SI>:  XYZ].U![
M\]#1SCGCZ49]SUH .:._UHX].F3TH^GKS0 >PR..]'^>E [#^E [<YS0 =N,
M].,T=^OZ4A(QSMZ'O2GTY/M0 >N#1G_.*.N<].F*.: #KC\^10/K^8H[]LBD
MZXZ$_7I0 N#V-!Z?_6I!C'''8$"E[\#\: #O0/;I[TG'UZ<TO7O@].* #GOV
M]*/PZ'O2<'.,'O1Q[<F@!1UZYZT9^OY4=<<^_% Z#G(QUH .>W\J._?TI#SU
M SCUI>]  /7M]*.OX].*,CKU[CBCN?KVH .#Z]/>CVYZT?>[Y'IBCGOQ^- !
M^'Y4=NO;C(HX!_'O1^9X].M  /4'K1T_&DX/OD<GU%+]!R: #Z9_&CVYZT'_
M  ZT<^@_.@ ^G?GD4=\\T'TX]J/Q/<=* #Z]>M /3D'(_.CTXQWH].3Z=* #
MMDD8QG(H[<_I29]QP.II?SSZT &/K^='3OW[T<9Z?I1QV&/PH /Y]J",_P#Z
MZ/3MSVI./KTYQUH 7OCU%'Y@G]*/IQ2<=!QG\Z %Z\BC/^<4=>W!'.:.: #C
M .2*/KZ]J/Q],@4<9]#G\Z #Z>O>C'K^E'XX/I2<<<>_2@!>O4=NHHQ_G-)Q
MCD@Y'.!UI>,]._I0 <<]>GO0>_;GK2=N.!CBE[\8&3^= !WZCK0?0=?I1WXQ
MR>U';C@>OO0 <T=L ]N,T=_7!_*C/N>!Z4 '3FCOQ_*@8'0>W2D/0Y].AZ4
M+W_'THYH[G)X%'MNH /3VZ]J/3D]?2D/Y_44OXGKZ4 '4 YSGTHY]1^5 ZCG
MMWHX[<?A0 =^_K0/;/0=:,<$<GCKFCG/<<4 &<=?T%'K]:/U/:C\3^5 %'6A
M_P 2._[_ +A^^.QI^E8_L>RP<_N$Y'?Y14>M?\@&_P 8_P!0_N.AJ33 %TFS
M5CDB! <_04 6_89''>@'GCTH'7KGK1Z<GIZ4 +1110 G<4#M[>]!]_RH]._/
M<4 'L3U':L>,C_A-;E<<_P!G1'.?^FDE;'3H!63&G_%87+\_\>$(]O\ 624
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M:D<8S ?_ (JD>'6#G;>68],V[<?^/5H_B>M&.>@ZT 9IAUL\B]L@?3[.V/\
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M[FM#3K[6AXJ^QSR3&*.9HMLB,0T( P^0N,DG.<]\<4 =!Y&O8YOK#IVMF_\
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M\^T/_? H^R6V"/L\6#U^04 0?VMIG0ZC:$XY_?+C^= UG2RNX:C:8'_39?\
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M>M ![XZ]11[X]?K2<<8[].>M'OQQGF@!>G;IWI.@_N@#\J7/7D<"@]?3L,T
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M1'D]2W7^52_\)!?:AK.FV\MPMK,NI*CV: Y>/RF;?N/5230!WF!_=]:7N/\
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M/3L?YT !X^O;WH/?TZ\\TO//YTF .P_+\J #CGA<#K2]NO3K@4>_.!FCGC-
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M(]\38RK<@X.>:F! '8#IQ28]CUSVH_QXR: %SSBC\*3MZ]^._P"-+WS@=>M
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M6D';\SU% !SCOT]J,XS@_F>]' '('0YR*7N3Z=>] "=.N?KF@^_MVHZ#T/\
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M@"@+*]QC^U).G>):4V5[D8U-P1_TR6KWN<],]*7GH.W3WH S_L5Z/^8J_O\
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M*>NAE<8U?5&[\SC_  K6[YP.O./\^E';GTY.: ,HZ&2V?[6U3KT$X_PIHT+
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:I[4 \ GTSG/%'?./7M1W]3[T .HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g2018032803585162931798.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018032803585162931798.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  J <4# 2(  A$! Q$!_\0
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M)&C!N%?J1GJ&R,D?>XSFIM)/A31;YM)TN73;:\F;#6T4B^8Q4=",YR!V[#-
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)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
